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The objectives of this study were to determine: the effects of maternal melatonin 
(MEL) supplementation during late gestation on the histological and molecular 
regulation in the Longissimus dorsi (LM) muscle of fetal bovine offspring, composition 
and gene expression of fetal perirenal (PR) adipose tissue, and LM gene expression in 
postnatal offspring at birth and d 195 of age. Maternal supplementation of MEL during 
late gestation resulted in no difference in calf fetal body weight or birth weight. However, 
at d 195 of age, calves from MEL treated dams had an average body weight increase of 
20 kg. Fetal LM weight and length tended to be increased in calves from MEL treated 
dams. Fetal gene expression of calves from MEL treated dams resulted in: increased LM 
adenosine monophosphate-activated protein kinase-α (AMPK) and decreased PR 
adiponectin (ADIPOQ), CCAAT enhancer binding protein alpha (CEBPA), proliferator 
activated receptor gamma (PPARg), and stearoyl-CoA desaturase (SCD). The improved 
metabolic status of LM coupled with the decrease in adipogenic gene expression, could 
result in calves from MEL treated dams having improved lean muscle accretion and 
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Prenatal myogenic and adipogenic development are a large determinant of a 
livestock animal’s future postnatal production potential. Changes in the uterine 
environment during fetal development can alter offspring future growth potential and 
result in impaired growth with increased risk of diseases (Barker, 1997, 2004, 2007; 
Nathanielsz et al., 2007). This manipulation of the fetus leads to the concept of fetal 
programming. Fetal programming, also known as developmental programming, is a 
change in the growth and/or developmental trajectory due to a stimulus or insult during a 
critical time in development for the fetus resulting in persistent effects to development 
and production (Nathanielsz et al., 2007). Growth of livestock can be broken into various 
phases that roughly coincide with the putative stages of production. The phases for 
livestock growth consist of: conception to birth, birth to puberty, and puberty to maturity, 
with harvesting of animals preceding maturity. The first critical time point in growth for 
livestock is during prenatal development. The fetus at this point is completely dependent 
on the dam for nutrients. These nutrients are in maternal circulation and must cross over 
to the fetus through the placenta. The flux of nutrient substrates from dam to fetus is
 
1 
dependent on the activity and accessibility of nutrient-specific transporters (Brett et al., 
2014) as well as uterine blood flow (Reynolds and Redmer, 1995). Maternal 
uteroplacental blood flow increase exponentially throughout gestation in both sheep and 
cattle to sustain a growing fetus (Reynolds and Redmer, 1995; Meschia, 1983). In sheep 
with compromised pregnancies, both over- and undernutrition led to decreased placental 
vascularity and reduced fetal weight (Chandler et al., 1985; Leury et al., 1990; Newnham 
et al., 1991; Kelly, 1992; Arnold et al., 2001; Wallace et al., 2002; Redmer et al., 2004; 
Luther et al., 2005; Lemley et al., 2013). In rats, decreasing placental blood flow in the 
last trimester of gestation led to reduced placental weight, fetal weight, and litter size, 
confirming the role of placental blood flow in fetal growth restriction (Anderson et al., 
2005). Several studies have shown that as blood flow increases throughout gestation, 
nutrient transport increases (Reynolds and Redmer, 1995; Reynolds et al., 2010). This 
increase in nutrient transport is not an increase in nutrient extraction per unit of blood, but 
due to an increase in placental perfusion and umbilical blood flow (Reynolds et al., 
2010).  
As previously mentioned, nutritional status of the dam and uteroplacental blood 
flow to fetus during gestation are scenarios that can lead to developmental programming 
of the offspring’s long term metabolic efficiency and productivity. Research on 
nutritional effects on fetal development has shown overnutrition of dams during gestation 
to increase adipogenesis and fibrogenesis in fetal skeletal muscle (Duarte et al., 2014). 
Likewise, undernutrition has shown to decrease myofibril number and increase myofibril 
cross-sectional area (Funston et al., 2010). These scenarios indicate that muscle and 
adipose tissues are prone to manipulation during prenatal development and can be altered 
 
2 
to effect carcass quality and value. Based on these findings, providing optimal levels of 
nutrition to the dam and trying to enhance uteroplacental blood flow or counter restricted 
blood flow during gestation can lead to increased nutrient transport to the fetus, 
supporting proper development.  
Since the dam is the sole source of nutrients to the developing fetus, strategies to 
maximize nutrient delivery and blood flow are needed in normal and compromised 
pregnancies to ensure proper development. Therapeutic supplements such as 
phosphodiesterase 5-specific inhibitors, have shown success in increasing blood flow. 
The vasodilatory action of these agents occurs through the action of nitric oxide (NO) 
inhibiting the breakdown of cyclic guanosine monophosphate (cGMP), resulting in 
relaxation of vascular smooth muscle (Michel, 2006). However, current literature is 
lacking data on the effects therapeutic blood flow supplements on uteroplacental 
hemodynamics in models of rescuing fetal growth restriction. Supplementation of 
melatonin (MEL) is currently being investigated as a novel approach on increasing 
uteroplacental blood flow (Richter et al., 2009; Lemley et al., 2012; Brockus et al., 
2016b).  
Melatonin is a natural hormone produced from the pineal gland and derived from 
tryptophan acting as a vasodilator, strong antioxidant, and signaling molecule for 
regulating natural circadian rhythm (Richter et al., 2009). Melatonin has also been shown 
to play a significant role in promoting the recruitment of brown adipose tissue (BAT) in 
newborn sheep (Seron-Ferre et al., 2015) as well as the browning of inguinal white 
adipose tissue in juvenile rats (Jimenez-Aranda et al., 2013). Brown adipose is extremely 
important in newborns due to its thermogenic properties. However, the fetal pineal gland 
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does not produce MEL, so all melatonin must come from maternal circulation. With the 
supplementation of MEL to the dam during gestation, maternal concentrations will 
increase thus increasing fetal concentrations. This increase in MEL leads to increased 
blood flow of the dam, thus amount of nutrients available to the fetus and with increased 
BAT recruitment can result in decreased newborn mortality (Carstens et al., 1997). A 
study conducted by Brockus and colleagues (2016a) found that Holstein calves from 
dams supplemented MEL during their last trimester of gestation, had significantly higher 
body weights at 8 to 9 weeks of age. They hypothesized that MEL supplementation to 
dams during late gestation possibly led to a response in the offspring resulting in 
developmental changes in skeletal muscle (Brockus et al., 2016a). 
 Therefore, the objectives of this study were to determine: the effects of maternal 
MEL supplementation during late gestation on the histological and molecular regulation 
in the Longissimus dorsi (LM) muscle of fetal bovine offspring, composition and gene 
expression of fetal perirenal (PR) adipose tissue, and LM gene expression in postnatal 
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2.1 Fetal Programming in Humans and Livestock 
The time and prevailing environmental conditions that humans and animals are 
subjected to while in utero leads to long term developmental and economic 
consequences. In child health and development, fetal growth restriction resulting in low 
birth weight infants’ effects on average over 350,000 infants a year in the U.S. totaling 
approximately $363,000 per child in long term medical bills (Luther et al., 2005; Wallace 
et al., 2006; NVSR, 2009). The effects of low birth weight not only impact the neonate’s 
short-term chances of survival, it extends into adolescence and adulthood potentially 
impacting their long-term quality of life. Lifelong consequences of developmental 
programming can be linked to increased risk of cardiovascular disease, obesity, diabetes, 
immune dysfunction, stunted growth, and more (Barker, 2004, 2007). Fetal programming 
due to growth restriction is not only an issue in humans, but in livestock species as well.  
In livestock, long-term health consequences resulting from a compromised uterine 
environment are not as impactful due to their relatively short lifespan. Instead, livestock 
animals affected by fetal programming can have dramatically altered carcass composition 
which results in increased adiposity and reduced meat yield and quality. This decrease is
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production potential leads to inferior animals that take more resources to reach market. 
Fetal growth restriction in livestock occurs commonly from poor nutritional environment 
of the dam during gestation. Factors that influence the nutritional environment of the dam 
consist of: animals that have multiple fetuses or litters; genetically selecting for greater 
milk production; and the breeding of livestock during warm seasons with higher 
temperatures and poor-quality forage with no supplementation (Wu et al., 2006). As 
researches have witnessed with humans, fetal programming in livestock results in 
increased neonatal mortality and morbidity. A larger issue with livestock is the reduced 
production of affected offspring that consist of: decreased growth rate due to reduced 
efficiency and ADG, poor carcass composition that contain higher amounts of adipose 
tissue with reduced myofibril numbers and increased connective tissue that results in 
inferior meat quality, and many diseases and other disorders (Wu et al., 2006; Reynolds 
et al., 2006). 
Environmental stressors such as nutrition of the dam can impact proper placental 
development, leading to reduced placental vascular function and compromised fetal 
growth. These stressors without maternal adaptation during gestation can reduce 
uteroplacental blood flow by hampering proper vascular bed formation resulting in fetal 
growth restriction or death (Vandenbosche and Kirchner, 1998; Funston et al., 2010; 
Vonnahme et al., 2013). Nutrient restriction of the dam during early to mid-embryonic 
development in cattle may appear to be unimportant due to size and requirements of the 
fetus during this time and research has shown that 75% of fetal growth and development 
occurs in the last 2 months gestation (Robinson et al., 1977). This, however, is a very 
important time as maximal placental growth, differentiation, and vascularization, along 
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with fetal organogenesis is occurring which lays the foundation for long-term future 
development of the fetus (Funston et al., 2010). Restrictions during this phase could 
reduce the size of the placenta and capacity for nutrient transfer influencing fetal growth 
and development resulting in reduced birth weight and inferior growth and production 
(Robinson et al., 2014). A study by Long and colleagues in 2010 found that restricting 
heifers at 55% of NRC recommendations for early gestation resulted in no change to birth 
weight, postnatal growth, or carcass characteristics (Long et al., 2010). However, the 
offspring from this study exhibited larger myofiber cross-sectional area (Long et al., 
2010). Overall findings of early gestation nutrient restriction show a tendency for the 
offspring to have reduced myofiber number due to intrauterine growth retardation 
(Robinson et al., 2013). 
 Mid to late-gestational nutrient restriction can occur with rising nutritional 
demands of the fetus. Restrictions in cattle at this point in fetal development can lead to 
increased perinatal mortality, reduced birthweights, and reduced postnatal growth 
(Kroker and Cummins, 1979). Fetal muscle development in cattle initially occurs within 
the first 2 months post-conception, though very few muscle fibers are formed during this 
time, the impact from nutrient restriction isn’t as detrimental (Russell and Oteruelo, 
1981). Most of muscle cell formation occurs between 2 and 8 months of gestation with 
insults to growth resulting in detrimental effects to muscle fiber number leading to 
irreversible effects on meat composition throughout life (Russell and Oteruelo, 1981; Zhu 
et al., 2006, Du et al., 2010). Developmental programming not only impacts yield of meat 
due to reduction of muscle fiber numbers, but also negatively impacts meat quality. 
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 Meat tenderness and palatability are very important to consumers, with tenderness 
rated as the most important contributor to beef palatability in the United States 
(Koohmaraie et al., 2002). The tenderness of meat is made up of a contribution of several 
effects that include muscle fiber size and density, solubility of connective tissue (mainly 
collagen), and the amount and distribution of marbling. Understanding the critical time 
point in development for the muscle, adipose, and connective tissue components within 
skeletal muscle and how they can be altered, is imperative for the economics of the meat 
industry. Each tissue and their fetal development will be discussed in further detail 
below. 
2.2 Muscle Development in Cattle 
 In the livestock industry, animals raised for their skeletal muscle provide meat for 
consumer demands. Skeletal muscle is a heterogeneous tissue made up of myocytes, 
adipocytes, and fibroblasts, with the ratio of the cells determining muscle composition, 
product yield, and meat quality. During fetal development, muscle accretion is 
accomplished through myofiber hyperplasia and hypertrophy. This differs from postnatal 
muscle accretion since the total number muscle fibers are determined before birth and 
myofibers can no longer undergo hyperplasia; therefore, postnatal muscle accretion is the 
result of hypertrophy of existing fibers (Du et al., 2010). The developmental foundation 
for each skeletal muscle group begins with a finite pool of multipotent mesenchymal 
stem cells that differentiate into mostly myocytes, with the remainder committing to 
either adipocytes for intramuscular fat accumulation sites, or fibroblasts for structural 
connective tissue (Dodson et al., 2010; Du et al., 2010; Yan et al., 2012). The number of 
cells that commit to each of these lineages can be altered by environmental stressors such 
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as nutritional status of the dam, however, primary muscle fiber number seems to be 
resistant to such influences (Dwyer et al., 1994; Zhu et al., 2006; Duarte et al., 2014). 
Skeletal muscle development initiates via mesenchymal stem cells receiving signals from 
neighboring tissue promoting their differentiation into myoblasts (Kollias and 
McDermott, 2008; Du et al., 2010). These signals consist of Wingless and Int (Wnt) and 
Sonic hedgehog which regulate the expression of paired box 3 and 7 (Pax3, Pax7). The 
activation of Pax3 and Pax7 then leads to the activation of myogenic regulatory factors 
such as myogenic factor 5 (Myf5), myogenic differentiation 1 (MyoD), and myogenin 
(MyoG) (Buckingham, 2001; Kassar-Duchossoy et al., 2005; Du et al., 2010). Various 
myogenic regulatory factors work together to promote differentiation of proliferating 
myoblast into multinucleated myotubules, eventually forming mature muscle fibers 
through a process known as myogenesis (Keren et al., 2006; Kollias and McDermott, 
2008; Du et al., 2010). Fetal muscle development, or myogenesis, can be broken up into 
two stages. First stage of myogenesis begins in early embryonic development with 
myocytes proliferating into primary muscle fibers (Du et al., 2010). These primary fibers 
are the foundation to which muscle groups form, acting as scaffolding for muscle fibers 
to replicate. The second stage of myogenesis is responsible for the majority of myofibers 
that make up skeletal muscle. This is especially important since secondary myogenesis 
ends before birth, resulting in the offspring’s total muscle fiber number and future 
production potential being established before birth (Stickland, 1978; Karuatatne et al., 
2005; Du et al., 2010).  
In cattle, primary muscle fibers begin developing within the first 2 months and 
roughly ends by 4 months post conception. Secondary muscle fibers begin forming 
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between 2 to 8 months post conception (Russell and Oteruelo, 1981). Since the majority 
of muscle fibers are established at this time, maternal nutritional insults during this mid- 
to late-gestational period can lead to irreversible reduction in myofiber numbers (Zhu et 
al., 2006). In sheep, maternal nutrient restriction during mid- to late-gestation resulted in 
reduced total secondary muscle fibers (Zhu et al., 2004). In pigs, maternal undernutrition 
from days 20 to 90 of pregnancy reduced piglet birth weight and muscle fiber number 
(Dwyer et al., 1994).  
Another factor controlling prenatal and postnatal metabolism and muscle 
development is the insulin-like growth factor signaling system (Bass et al., 1999; Holt et 
al., 2012; Gonzalez et al., 2013). In this system, insulin-like growth factor 2 (IGF2) is 
mainly responsible for fetal growth and muscle development as insulin-like growth factor 
1 (IGF1) is mainly responsible for postnatal growth and muscle development (Florini et 
al., 1991; Haig and Graham, 1991; Braxton et al., 1993; Bass et al., 1999; Le Roith et al., 
2001; Gluckman and Pinal, 2003; Gonzalez et al., 2013). Liu et al. in 1993, looked at the 
effects of IGF1, IGF1 receptor (IGF1R), and IGF2 on fetal growth and development. 
They found that knocking out IGF1R led to dwarfism and neonatal lethality, and that the 
reduced body weight was attributed to suppressed muscle fiber hypoplasia rather than 
hypertrophy in mice (Liu et al., 1993). Adams and Haddad (1996) found that rats with 
increased IGF1 resulted in increased muscle mass, fiber size, and protein-to-body weight 
ratio, and that IGF1 expression preceded muscle fiber hypertrophic phase.  
As stated above, restricted offspring have permanent changes to muscle fiber 
number and size. They develop with lower muscle fiber numbers with each fiber being 
larger than normal (Foxcroft el al., 2006; Alvarenga et al., 2013). This is due to the 
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inverse relationship between muscle fiber size and number (Rehfeldt and Kuhn, 2006). 
This permanent reduction in muscle fiber number inhibits the potential for postnatal 
catch-up of low birth weight offspring with those born without restrictions. Hypertrophy 
of existing muscle fibers is the only form of postnatal muscle accretion. Reduced muscle 
fiber numbers reduce meat yield and increased myofibril size that leads to reduced meat 
quality (Klosowska et al., 1979; Fiedler et al., 1999). These data indicate that livestock 
species in mid- to late-gestation are susceptible to fetal programming that can result in the 
permanent reduction in muscle cell number and growth trajectory ultimately reducing 
productivity and efficiency.  
2.3 Adipose Development in Cattle 
In addition to superior muscle development, producers would like to increase 
intramuscular fat deposition (marbling) within skeletal muscle without wasting excessive 
resources into undesirable adipose depots such as visceral, subcutaneous, and 
intermuscular adipose depots. This is due to marbling contributing to the flavor and 
juiciness of meat, increasing economic value as marbling increases (Crouse et al., 1983; 
Hausman et al., 2009; Du et al., 2017). The extent of adipogenesis during fetal 
development is critical for determining the amount of marbling that can develop 
postnatally. Adipose accumulation in visceral, subcutaneous, and intermuscular depots 
lowers the efficiency and economic value of livestock. This leaves researchers with the 
task of selectively enhancing marbling deposition, which is the last adipose depot to 
accumulate fat, while limiting formation and accretion of adipose tissue in the higher 
metabolic priority, yet more undesirable depots (Crouse et al., 1983; Mir et al., 2002; 
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Hausman et al., 2009; Du et al., 2017). The fetal period is an underappreciated window to 
selectively impact these depots.  
The total mass or volume of adipose tissue is determined by the number of 
adipocytes and their respective size (Spalding et al., 2008). During the fetal stage, 
adipogenesis starts with mesenchymal stem cells that can either differentiate into 
myocytes, adipocytes, or fibroblasts. When mesenchymal stem cells commit to the 
adipogenic lineage, starting around mid-gestation, they become future sites for adipose 
tissue accretion and lipid accumulation. Permanent differentiation into adipocytes 
requires self-reinforcing regulation of transcription factors CCAAT enhancer binding 
protein (CEBP) and peroxisome proliferator activated receptor gamma (PPARg) (Clarke 
et al., 1997; Wu et al., 1999). When CEBP alpha (CEBPA) is induced and binds to the 
promoter of PPARg, it activates the expression of PPARg which further stimulates the 
expression of CEBPA (Clarke et al., 1997; Wu et al., 1999). With the activation and 
expression of PPARg, terminal adipogenic differentiation is achieved through the 
induction of many genes that are important for triglyceride uptake and storage (Frohnert 
et al., 1999; Rosen and MacDougald, 2006).  
Maternal manipulation strategies can be applied during early fetal development, 
to alter mesenchymal stem cell commitment into adipocytes to enhance adipogenesis 
(Feve, 2005). This can result in improved intramuscular fat and meat quality; however, it 
can also lead to over fattening, decreased feed efficiency, and lower retail yield. Studies 
with nutrient-restricted mothers have shown adipose tissue development impaired, but 
due to adipose tissue plasticity, offspring born to restricted mothers often have 
compensatory gain of adipose tissue leading to fatter offspring with decreased feed 
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efficiency and lower muscle mass (Zhu et al., 2006; Wang et al., 2017). The overnutrition 
of pregnant ewes fed 150% of NRC requirements (NRC, 1985) has shown to increase 
adipogenesis in skeletal muscle (Tong et al., 2008, 2009). This increased adiposity in 
skeletal muscle can result in higher quality grades increasing the value of the carcass, 
though it increases external fat as well due to intramuscular deposition being last in 
priority. This increase in other fat depots lowers the yield grade of carcasses due to trim 
loss resulting in a decrease in closely trimmed retail cuts. However, in cases of maternal 
undernutrition, adipose tissue development is impaired, but due to adipose tissue 
plasticity, offspring born to restricted mothers often have compensatory gain of adipose 
tissue (Zhu et al., 2006; Wang et al., 2017). The chronological formation of adipose 
depots may still hold the key to enhancing marbling while limiting overall adiposity. 
Intramuscular adipocyte development primarily occurs during late gestation up to 250 
days of age (Du et al., 2017). In beef cattle, providing high-energy supplementation to 
early weaning calves before 250 days of age will enhance intramuscular formation 
resulting in increased marbling during fattening stages (Corah and McCully, 2007; Du et 
al., 2013). While postnatal feeding strategies can be used to enhance the accretion of 
these depots, the initial foundation of cells and lipid accumulation within begins during 
fetal development (Corah and McCully, 2007; Du et al., 2013).  
In livestock, dietary energy that is above the metabolic needs of the animal is 
stored as adipose tissue and can lead to obesity if left uncontrolled. Though in some 
mammalian species, excessive energy storage during specific times of the year is needed 
to survive. These mammals exhibit seasonal changes in adiposity that are induced either 
by changes in photoperiod or an endogenous clock (Bartness et al., 2002). These seasonal 
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changes effect lipid storage in white adipose tissue (WAT; the major storage of energy in 
mammals) and brown adipose tissue (BAT; responsible for heat production via 
thermogenesis). These environmental ques are critical for the secretion of melatonin, a 
naturally produced hormone that is secreted by the pineal gland, and its role with 
maintaining natural circadian rhythm.  
2.4 Intramuscular Fibrogenesis in Cattle 
 Connective tissue not only plays a role with muscle physiology but is a major 
determinant of consumer perception of meat tenderness which reported to be the single 
most desirable characteristic of beef to consumers (Huffman et al., 1996). The connective 
tissue that underlies this meat quality trait arises from fibroblast during early 
development and begins with commitment of mesenchymal stem cells to the myogenic, 
adipogenic, or firbogenic lineage (Aguiari et al., 2008; Kuang et al., 2008; Yablonka-
Reuveni et al., 2008). These connective tissues in various types of muscles serve as 
structural support by binding muscle cells together and insuring proper alignment, or to 
contract providing motion (Borg and Caulfield, 1980). There are three layers of 
connective tissues within skeletal muscle: epimysium surrounds the entire muscle, 
perimysium is a sheath surrounding bundles of muscle fibers, and endomysium surrounds 
individual muscle cells (Borg and Caulfield, 1980). These connective tissues are made up 
in large part by collagen and collagen cross-links, that provides a strong and elastic 
support. Connective tissue development is also influenced by growth retardation that 
results in increased collagen content along with an increase in adipogenesis within fetal 
skeletal muscle (Duarte et al., 2014). Studies investigating fibrogenesis in overfed ewes 
and malnutrition sows have both shown that insults to the nutrient environment of the 
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dam can program the fetus to have increased fibrosis which impairs muscle function and 
increase meat toughness (Huang et al., 2010; Karunaratne et al., 2005).  
2.5 Therapeutic Melatonin Supplementation in Normal and Compromised 
Pregnancies 
 In compromised pregnancies, reduced uterine blood flow and placental 
vascularity leads to reduced umbilical blood flow with inferior nutrient delivery resulting 
in fetal growth restriction (Thureen et al., 1992; Rigano et al., 2001; Wallace et al., 2002; 
Regnault et al., 2003; Kwon et al., 2004; Reynolds et al., 2005). Low birth weight 
offspring born to dams with compromised pregnancies have slower growth rates, 
increased chances of diseases, and increased postnatal adiposity (Barker and Clark, 1997; 
Zhu et al., 2006). Therefore, studies have experimented with therapeutic treatment of 
compromised pregnancies and blood flow with the use of vasodilators.  
Melatonin (MEL) is a highly conserved compound that exhibits numerous 
receptor mediated and receptor independent physiological effects. Melatonin is produced 
by the pineal gland in the mammalian brain and in addition to its best-known effects on 
circadian rhythm (Reiter, 2003), it is a powerful scavenger of free radicals (Reiter et al., 
1995; Manchester et al., 2015), involved in vasodilation (Lemley et al., 2012; Brockus et 
al., 2016b), and tissue level metabolism (Ha et al., 2006; Torres-Farfan et al., 2008; 
Stratos et al., 2012). Our understanding of the function of MEL begins with its discovery 
and isolation by Aaron Lerner and colleagues at Yale University (Lerner et al., 1958) 
who hoped to use it as a treatment for reversing the darkening effects of melanocyte 
stimulating hormone on skin (Lerner et al., 1958). Melatonin was later suggested to play 
a role in affecting the brain, gonads, and other neuroendocrine systems (Wurtman et al., 
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1968; Reiter et al., 1978). The pineal gland secretes melatonin during the absence of light 
induced stimulus (Axelrod et al., 1964). Light is first detected by retinal ganglion cells 
and transmitted via a multisynaptic pathway to the pineal gland (Larsen et al., 1998). This 
neurochemical signal of photoperiod is delivered by the sympathetic nervous system 
(SNS) and causes pinealocytes to secrete an endocrine signal into the bloodstream, MEL. 
Light stimulus causes an interruption in the negative feedback loop needed for MEL 
secretion, blocking the effects on short-day seasonal reproduction systems and seasonal 
changes in adiposity (Bartness et al., 1984; Vitale et al., 1985; Moore, 1996).  
The potential for MEL to prevent or rescue compromised pregnancies has gained 
interest in recent years. Studies in MEL supplementation to sheep with compromised 
pregnancies has shown to alter uteroplacental hemodynamics and fetal development 
(Lemley et al., 2012, 2013). Likewise, in pregnant Holstein heifers, blood flow was 
improved with supplemental MEL during late gestation resulting up to a 25% increase in 
uterine blood flow of MEL treated heifers compared to control (Brockus et al., 2016b). 
Offspring born to MEL supplemented Holstein heifers exhibited significantly greater 
body weights at 8 to 9 weeks of age (Brockus et al., 2016a). 
Once secreted, MEL exhibits its direct effects through binding to MEL receptors 
on various tissues (Bartness et al., 2002). The known MEL receptors include MT1 and 
MT2 (Dubocovich et al., 1998, 2010) and their presence has been detected on peripheral 
tissues including muscle (Stratos et al., 2012) and adipose tissue (Le Gouic et al., 1997). 
In skeletal muscle, binding of MEL to these receptors stimulates glucose transport into 
muscle cells (Ha et al., 2006), increases the number of satellite cells, reduces 
inflammation, and inhibits apoptosis by modulating associated signaling pathways 
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allowing for cell regeneration (Stratos et al., 2012). Melatonin increased insulin receptor 
substrate-1 is phosphorylated and the activity of phosphatidylinositol 3-kinase is 
increased, resulting in increased glucose uptake (Ha et al., 2006). In adipose tissue, a 
study supplementing rats with 0.4 μg/ml of MEL in water bi-weekly found a reduction in 
intra-abdominal adiposity by 20%, plasma leptin (ng/ml) by 33%, and plasma insulin 
(ng/ml) by 25% (Wolden-Hanson et al., 2000). Seasonal studies show a positive 
correlation between increased adiposity and MEL levels (Bartness et al., 1984; Wade et 
al., 1984; Bartness et al., 1985). This increase in the sympathetic drive causes an increase 
in release of norepinephrine, which effects WAT and BAT. Melatonin indirectly effects 
WAT through increased norepinephrine and epinephrine which results in increased 
lipolysis (Youngstrom and Bartness, 1998; Demas and Bartness, 2001). Norepinephrine 
stimulates increased BAT thermogenesis through cAMP-PKA signaling cascade that 
causes the phosphorylation of PKA to activate hormone sensitive lipase (HSL) 
(Townsend and Tseng, 2012). Hormone sensitive lipase cleaves triglycerides into free 
fatty acids that are shuttled into the mitochondria to undergo β-oxidation for ATP 
production or activate uncoupling protein 1 (UCP1) to produce heat via thermogenesis 
(Townsend and Tseng, 2012). Thermogenesis is important for heat production in 
newborns, increasing survival and homeothermy (Himms-Hagen, 1990). This links BAT 
thermogenesis to newborn mortality rate, in which potentially increasing BAT 
recruitment or thermogenic properties could lead to a decrease in newborn loss due to 
hypothermia (Carstens et al., 1997). Studies in various species have shown MEL to 
increase the amount of BAT (Jimenez-Aranda et al., 2013; Seron-Ferre et al., 2015), 
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however MEL’s mechanism of action on BAT recruitment is still unknown (Bartness et 
al., 2002). 
Given its widespread role in central and peripheral metabolism and physiological 
function, MEL has shown promise as a potential therapeutic agent to prevent or rescue 
compromised pregnancies. In addition, given its role in directly modulating muscle 
growth and repair as well as modulating brown and white adipose tissue metabolism, 
MEL supplementation during gestation has the potential to improve the development of 
these economically important tissues to improve efficiency and quality of beef 
production. The underlying tissue level responses in fetal carcass tissues to maternal 
MEL supplementation mechanisms have not been thoroughly investigated which is the 
objective of the current research. The operational hypothesis is that maternal 
supplementation of MEL during mid- to late-gestation programs the fetus for superior 
postnatal development and improved skeletal muscle growth through a combination of 
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EFFECT OF MATERNAL MELATONIN SUPPLEMENTATION DURING LATE 
GESTATION ON MUSCLE AND ADIPOSE TISSUE HISTOLOGY, GENE 
EXPRESSION IN 240 DAY OLD BOVINE FETUSES 
3.1 Abstract 
Melatonin is a natural hormone that is secreted by the pineal gland and has effects 
on economically important reproductive and carcass tissues including muscle and adipose 
tissue. There is evidence to suggest that supplemental melatonin to dams during late 
gestation may alter skeletal muscle development in fetal calves as documented by an 
increased postnatal weight of calves starting at 8 weeks of age (Brockus et al., 2006a). 
The objectives of this study were to determine the effects of maternal melatonin 
supplementation during late gestation on the histological and molecular regulation in the 
Longissimus dorsi (LM) of fetal bovine offspring and to determine the effects of 
maternal melatonin on composition and gene expression of perirenal (PR) adipose tissue. 
Beef heifers (n = 32) and cows (n = 25) consisting of purebred Angus, purebred 
Hereford, or crossbred genetics, were bred via timed-artificial insemination and assigned 
to one of two treatment groups. The treatment groups consisted of melatonin 
supplementation (MEL) or without supplementation (CON). Supplementation of MEL 
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was delivered via two- 24 mg implants with the CON receiving two placebo implants at 
days 180, 210, and 240 of gestation. After day 240 of gestation, dams received no further 
treatments and a subset of twelve crossbred heifers (n = 6 MEL; n = 6 CON) underwent 
cesarean section on day 243 ± 2 of gestation to collect fetal tissue samples. Samples 
consisted of LM, PR, umbilical artery and vein plasma, fetal trunk plasma, and maternal 
plasma. In this study, there was no difference (P > 0.05) in fetal body weight between 
calves from MEL treated dams compared to CON dams. Calves from MEL treated dams 
tended to have increased LM weight and length than that of calves from CON treated 
dams. Immunohistochemistry (IHC) analysis of fetal LM showed calves from dams 
treated with MEL having a tendency for increased PAX7 activated nuclei to total nuclei 
ratio. Relative gene expression of fetal LM identified calves from MEL treated dams to 
have increased adenosine monophosphate-activated protein kinase-α (AMPK). Maternal 
MEL supplementation during late gestation lead to no difference in fetal PR weight 
compared to CON treated dams. However, relative gene expression of fetal PR showed 
decreased adiponectin (ADIPOQ), CCAAT enhancer binding protein alpha (CEBPA), 
stearoyl-CoA desaturase (SCD), peroxisome proliferator activated receptor gamma 
(PPARg), insulin-like growth factor 1 (IGF1), and a tendency for decreased insulin-like 
growth factor 2 (IGF2). Maternal MEL supplementation during late gestation resulted in 
fetal programming of LM muscle and PR adipose tissues in the bovine offspring. 
3.2 Introduction 
With the rapidly increasing global population, the need for improving the 
efficiency of livestock and meat production is vital. Prenatal myogenic and adipogenic 
development are a large determinant of the animal’s future postnatal production potential. 
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Economically important tissues such as muscle and adipose are of a lower developmental 
priority compared to vital organs and nervous tissues (Zhu et al., 2006; Du et al., 2010). 
This leaves muscle and adipose tissue development particularly susceptible to the 
prevailing nutritional environment in utero (Zhu et al., 2006; Du et al., 2010). Stimuli 
and/or insults during the development of these tissues can set the stage for increased 
production efficiency, maximal growth, and superior carcasses, or lead to impaired 
growth, inferior carcass composition, and increased risk of morbidity and mortality. Fetal 
programming is a change in the growth trajectory due to a stimulus or insult during a 
critical time in development for the fetus resulting in persisting effects into the postnatal 
phases of life or production (Nathanielsz et al., 2007). The first of these critical time 
points in growth for livestock is during prenatal development, at which point the fetus is 
completely dependent on the dam for nutrients. Nutrients for the fetus are in maternal 
circulation and must cross over to the fetus through the placenta. The nutritional status of 
the dam can have long lasting effects on fetal development by permanently altering the 
development of adipogenesis, fibrogenesis, and myogenesis (Karunaratne et al., 2005; 
Rehfeldt and Kuhn, 2006; Zhu et al., 2006; Funston et al., 2010; Huang et al., 2010; 
Duarte et al., 2014; Wang et al., 2017). However, even with sufficient nutrients in 
circulation, the flux of nutrient substrates from dam to fetus is dependent on the activity 
and accessibility of nutrient-specific transporters (Brett et al., 2014) as well as uterine 
blood flow (Reynolds and Redmer, 1995). In humans and sheep, decrease placental blood 
flow in mid- to late-gestation reduced placental weight and fetal weight (Reynolds and 
Redmer, 1995; Ferrazzi et al., 2000; Konje et al., 2003; Reynolds, et al., 2005; Vonnahme 
et al., 2013; Eifert et al., 2015) while decreasing litter size in rats (Anderson et al., 2005). 
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The tissue level impacts in the fetus under these scenarios have not been as thoroughly 
discussed. 
Approaches to prevent or rescue compromised pregnancies include identifying 
agents and mechanisms to improve uteroplacental nutrient exchange and in turn augment 
the in utero nutritional environment experienced by the fetus. Among these, 
supplementation of melatonin has been investigated as a novel therapeutic approach to 
increase uteroplacental blood flow (Juaniaux et al., 2006; Paulis and Simko, 2007; 
Richter et al., 2009; Lemley et al., 2012 and 2013; Vonnahme et al., 2013; Eifert et al., 
2015; Brockus et al., 2016a and 2016b). Melatonin is a natural hormone produced from 
the pineal gland and derived from tryptophan. Melatonin has been described as having 
pleiotropic properties acting as a vasodilator, strong antioxidant, and signaling molecule 
for regulating natural circadian rhythm (Richter et al., 2009). The known melatonin 
receptors include MT1 and MT2 (Dubocovich et al., 1998, 2010) and their presence has 
been detected on peripheral tissues including muscle (Stratos et al., 2012) and adipose 
tissue (Le Gouic et al., 1997). In skeletal muscle, binding of melatonin to these receptors 
stimulates glucose transport into muscle cells (Ha et al., 2006), increases the number of 
satellite cells, reduces inflammation, and inhibits apoptosis by modulating associated 
signaling pathways (Stratos et al., 2012). Melatonin increased insulin receptor substrate-1 
is phosphorylated and the activity of phosphatidylinositol 3-kinase is increased, resulting 
in increased glucose uptake (Ha et al., 2006). Melatonin has decreased intraabdominal 
adiposity in rats (Wolden-Hanson et al., 2000). Melatonin has also been shown to play a 
significant role in promoting the recruitment of brown adipose tissue (BAT) in newborn 
sheep (Seron-Ferre et al., 2015) as well as the browning of inguinal white adipose tissue 
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(WAT) in juvenile rats (Jimenez-Aranda et al., 2013). Brown adipose is extremely 
important in newborns due to its thermogenic properties which can decrease newborn 
mortality (Carstens et al., 1997). Studies have found melatonin to cause increased hair 
follicle growth in goats (Nixon et al.,1993), cardiovascular influence (Pechanova et 
al.,2014), and decreased core body temperature in humans (Krauchi et al.,1997). 
However, studies looking at similar effects in cattle are lacking. A study conducted by 
Brockus et al. (2016a) supplemented Holstein heifers with melatonin to look at effects on 
offspring blood pressure, heart rate, liver blood flow, skin temperature, and hair growth. 
They found that calves from dams supplemented with melatonin during their last 
trimester of gestation, had significantly higher body weights at 8 to 9 weeks of age 
(Brockus et al., 2016a). They hypothesized that melatonin supplementation could have 
altered skeletal muscle development of the calves, providing impetus for the current 
study (Brockus et al., 2016a).  
Therefore, our hypothesis was that increased maternal melatonin concentration 
during late gestation alters the metabolic program of fetal skeletal muscle and adipose 
tissue. Additionally, the increased uterine blood flow will improve postnatal growth by 
programming increased myogenic mRNA gene expression in fetal skeletal muscle. The 
specific objectives of this study were to determine the effects of maternal melatonin 
supplementation on the histological and molecular regulation in the Longissimus dorsi 
(LM) of fetal bovine offspring and to determine the effects of maternal melatonin on 
composition and gene expression of perirenal (PR) adipose tissue. 
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3.3 Materials and Methods 
3.3.1 Animal Care and Treatment 
The current study was conducted under an approved Mississippi State University 
Institutional Animal Care and Use Committee protocol (#16-036). 
As part of a larger study, a total of 87 heifers and 65 cows that consisted of 
purebred Angus, purebred Hereford, or crossbred genetics, were bred via timed-artificial 
insemination (AI) at the H. H. Leveck Animal Research Center, Mississippi State 
University, MS. Heifers were bred on December 10, 2015, and cows were bred on 
December 21, 2015. At d 120 post-AI, heifers and cows were examined via 
ultrasonography to confirm pregnancy. This resulted in 32 heifers and 25 cows with 
confirmed conception. Then dams were blocked by bodyweight and randomly assigned to 
one of 2 maternal treatment groups. The 2 maternal treatment groups consist of a 
melatonin treatment (MEL; n = 29) and a no melatonin treatment (CON; n = 28). The 
MEL group was administered two ear impants (MelatoninImplants.com) containing 24 
mg MEL each, every 30 days starting at d 180 of gestation (baseline) and ending on d 
240 of gestation. The MEL implant on d 240 of gestation was expected to provide 
increased maternal MEL concentration approximately till d 270 of gestation. After d 270 
of gestation, all dams received no further treatments throughout the study. Furthermore, 
on d 180, 210, and 240 of gestation, uterine blood flow was measured via 
ultrasonography; with serum, plasma, hair scores, and thermal images also collected from 
each treatment group. Both maternal treatment groups were managed the same 
throughout the study and had access to similar dietary regimes with ad libitum water 
access. At d 240 of gestation (~85% gestation period), 12 heifers (n = 6 CON and n = 6 
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MEL) were randomly chosen to undergo Cesarean sections for collection of fetuses and 
fetal tissues. 
3.3.2 Cesarean Section  
Cesarean surgeries were performed by veterinarians from the Mississippi State 
University College of Veterinary Medicine. Once removed from the uterus, each fetal 
calf was weighed, exsanguinated, and then weighed again to determine pre- and post- 
exsanguination weights. Fetal tissue samples collected consisted of: LM, PR, and blood 
for plasma and serum collection. For LM muscle samples, each sample was portioned 
into two 1 cm by 1 cm samples and stored in cryotubes, tissue embedding molds, and 
then stored at -80°C until further analysis. Tissue embedding consisted of a 1 cm by 1 cm 
section of muscle placed in Optimal Cutting Temperature (OCT) tissue embedding 
media (Fisher Scientific, Pittsburgh, PA), and frozen by submersion in supercooled 
isobutane. For PR adipose samples, each sample was sectioned into 500 mg samples and 
stored in cryotubes and sterile whirlpack bags, then stored at -80°C until further analysis. 
Blood was collected in red and purple top tubes for collection of serum and plasma, 
respectively. The samples were then spun down via centrifuge, with the supernatant layer 
extracted via pipetting and portioned into cryotubes and stored at -80°C until further 
analysis. 
3.3.3 Analysis of Fatty Acids 
 Fatty acids were extracted from maternal plasma, fetal plasma, fetal umbilical 
artery and vein plasma, and fetal PR adipose tissue, then esterified using a 
transesterification method (O’Fallon et al., 2007). For extraction, 500 μl of plasma 
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samples and 0.1-g of PR samples were placed into a 20-ml flat bottom glass vial with 
PTFE-lined silicon septum (Fischer scientific, Waltham, MA, USA). After, 200 μl (1-ml 
for PR) of methyl tridecanoate (150 mg/ml in methanol; MeOH) was added as internal 
standard (Sigma Aldrich, St. Louis, MO), fat was saponified in presence of 700 μl of 
potassium hydroxide and 5.3-ml of methanol. Saponified FAs were then trans-esterified 
in 580 μl of sulfuric acid resulting in fatty acid methyl esters (FAME). Fatty acid methyl 
esters were extracted in 600 μl (3-ml for PR) of hexane, transferred into a 2-ml amber 
vial, and stored in -20°C freezer until being determined by gas chromatography (GC). 
For analysis, FAME were separated and quantified using a GC system (Agilent 
Technologies, Santa Clara, CA) equipped with an HP- 88 capillary column (30 m × 0.25 
mm, 0.2 µm film thickness; Supelco Inc., Bellefonte, PA) and a flame-ionization 
detector. For carrier gas, hydrogen was used at 1.5 ml/min. Peaks were identified by 
FAME standards in Supelco® 37 Component FAME Mix (Sigma-Aldrich, St. Louis, 
MO), FAME #21 Mix (Restek, Bellefonte, PA), and a customized 17-component FAME 
mix (Nu-Chek-Prep, Elysian, MN) and were quantified by an internal standard 
calibration method. For each sample, concentrations (mg/g of adipose tissue) of FA was 
converted from the corresponding FAME concentration by using molecular weight ratios 
with percentages of each FA calculated by dividing its concentration (mg/g) by total FA 
concentration (mg/g) and then multiplying by 100. Saturation index (SI) was calculated 
by the ratio of SFA and the sum of MUFA and PUFA. 
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3.3.4 Longissimus dorsi Analysis of Relative Gene Expression 
3.3.4.1 QuantiNova™ SYBR® Green PCR Kit 
Nucleic acids were isolated from the LM biopsy samples using 700 μl of QIAzol® 
Lysis Reagent (QIAGEN, Hilden, Germany), followed by purification with the use of 
RNA using a miRNeasy® Mini Kit (QIAGEN, Hilden, Germany). Extracted total RNA 
was quantified using a NanoDrop One spectrophotometer (Thermo scientific, Waltham, 
MA). Samples exhibiting 260 nm/280 nm ratios between 1.9 and 2.1 were deemed 
acceptable for downstream procedures and stored at -80°C. For each sample, duplicate 
cDNA synthesis reactions were conducted using 100 nanograms of total RNA using 
QuantiNova™ Reverse Transcription Kits (QIAGEN, Hilden, Germany) according to the 
manufacturers protocol. The genes of interest for LM tissue included insulin-like growth 
factor 1 (IGF1), IGF1 receptor (IGF1R), insulin-like growth factor 2 (IGF2), IGF2 
receptor (IGF2R), cystatin (CYS), adenosine monophosphate-activated protein kinase-α 
(AMPK), lysyl oxidase (LOX), bone morphogenetic protein (BMP). Beta actin was used 
as a housekeeping gene. Gene specific primers for the genes of interest (Table 3.1) were 
designed and validated for quantitative PCR (qPCR). Primer efficiencies were 
determined by plotting the threshold cycle versus the log of the input concentrations for 
8, 10-fold serial dilutions of pooled LM muscle cDNA. Primer sets and assays with 
efficiencies between 0.9 and 1.1 were considered acceptable for real time PCR analysis. 
Each of the duplicate cDNA samples were subjected to duplicate qPCR reactions using 
QuantiNova™ SYBR® Green PCR Kit (QIAGEN, Hilden, Germany). A master mix 
containing SYBR® Green, forward and reverse primers (diluted 1:20), and ROX reference 
dye along with 300 ng of cDNA was pipetted into a 96-well MicroAmp® Fast Optical 
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Reaction Plate (Applied Biosystems, Foster City, CA). The plate was then covered with 
Masterclear real-time PCR Film (Eppendorf, Hamburg, Germany), briefly vortexed and 
centrifuged, then placed in QuantiStudio™ 3 (Applied Biosystems, Foster City, CA) for 
real-time qPCR analysis. Thermal cycling parameters used consisted of: a hold stage at 
95°C for 2 minutes; PCR stage with step 1 at 95°C for 5 seconds followed by step 2 at 
60°C for 10 seconds for 50 cycles; with a melting curve stage have step 1 at 95°C for 1 
second then step 2 60°C for 20 seconds and step 3 (dissociation) at 95°C for 1 second 
(capturing every 0.1°C/s). Replicate threshold cycle (CT) values were averaged and used 
for relative quantification using the 2−ΔΔCT method (Livak and Schmittgen, 2001). 
3.3.4.2 TaqMan™ fast advanced master mix 
Nucleic acids were isolated from the LM biopsy samples using 700 μl of 
QIAzol® Lysis Reagent (QIAGEN, Hilden, Germany), followed by purification with the 
use of RNA using a miRNeasy® Mini Kit (QIAGEN, Hilden, Germany). Extracted total 
RNA was quantified using a NanoDrop One spectrophotometer (Thermo scientific, 
Waltham, MA). Samples exhibiting 260 nm/280 nm ratios between 1.9 and 2.1 were 
deemed acceptable for downstream procedures and stored at -80°C. For each sample, 
duplicate cDNA synthesis reactions were conducted using 100 ng of total RNA using 
QuantiNova™ Reverse Transcription Kits (QIAGEN, Hilden, Germany) according to the 
manufacturer protocol. The genes of interest for LM were myogenic factor 5 (Myf5), 
myogenin (MyoG), myogenic differentiation 1 (MyoD), CCAAT enhancer binding 
protein alpha (CEBPA), stearoyl-CoA desaturase (SCD), peroxisome proliferator 
activated receptor gamma (PPARg), and patatin-like phospholipase domain containing 2 
(PNPLA2). Beta actin was used as a housekeeping gene. Assays for the genes of interest 
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(Table 3.2) were validated for efficiency and specificity prior to qPCR. Primer 
efficiencies were determined by plotting the threshold cycle versus the log of the input 
concentrations for 8, 10-fold serial dilutions of pooled PR adipose tissue cDNA. Primer 
sets and assays with efficiencies between 0.9 and 1.1 were considered acceptable for real 
time PCR analysis. Complementary DNA was amplified in duplicate using TaqMan™ 
fast advanced master mix (Thermo scientific, Waltham, MA). A master mix containing 
TaqMan™ fast advanced master mix and gene assay was pipetted along with 100 ng of 
cDNA into a 96-well MicroAmp® Fast Optical Reaction Plate (Applied Biosystems, 
Foster City, CA). The plate was then covered with Masterclear real-time PCR Film 
(Eppendorf, Hamburg, Germany), briefly vortexed and centrifuged, then placed in 
QuantiStudio™ 3 (Applied Biosystems, Foster City, CA) for real-time qPCR analysis. 
Thermal cycling parameters used consisted of: a hold stage at 50°C for 2 minutes; 
polymerase activation hold at 95°C for 20 seconds; PCR stage with step 1 at 95°C for 1 
second followed by step 2 at 60°C for 20 seconds for 40 cycles. Replicate CT values 
were averaged and used for relative quantification using the 2−ΔΔCT method (Livak and 
Schmittgen, 2001). 
3.3.5 Perirenal Adipose Analysis of Relative Gene Expression 
Nucleic acids were isolated from the PR biopsy samples using 700 μl of QIAzol® 
Lysis Reagent (QIAGEN, Hilden, Germany), followed by purification with the use of 
RNA using a miRNeasy® Mini Kit (QIAGEN, Hilden, Germany). Extracted total RNA 
was quantified using a NanoDrop One spectrophotometer (Thermo scientific, Waltham, 
MA). Samples exhibiting 260 nm/280 nm ratios between 1.9 and 2.1 were deemed 
acceptable for downstream procedures and stored at -80°C. For each sample, duplicate 
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cDNA synthesis reactions were conducted using 100 ng of total RNA using 
QuantiNova™ Reverse Transcription Kits (QIAGEN, Hilden, Germany) according to the 
manufacturer protocol. The genes of interest for PR adipose tissue were IGF1, IGF1R, 
IGF2, IGF2R, uncoupling protein 1 (UCP1), adiponectin (ADIPOQ), CEBPA, SCD, 
PPARg, and PNPLA2, with beta actin serving as housekeeping gene. Assays for the 
genes of interest (Table 3.3) were validated for qPCR. Primer efficiencies were 
determined by plotting the threshold cycle versus the log of the input concentrations for 
8, 10-fold serial dilutions of pooled PR adipose tissue cDNA. Primer sets and assays with 
efficiencies between 0.9 and 1.1 were considered acceptable for real time PCR analysis. 
Complementary DNA was amplified in duplicate using TaqMan™ fast advanced master 
mix (Thermo scientific, Waltham, MA). A master mix containing TaqMan™ fast 
advanced master mix and gene assay was pipetted along with 100 ng of cDNA into a 96-
well MicroAmp® Fast Optical Reaction Plate (Applied Biosystems, Foster City, CA). The 
plate was then covered with Masterclear real-time PCR Film (Eppendorf, Hamburg, 
Germany), briefly vortexed and centrifuged, then placed in QuantiStudio™ 3 (Applied 
Biosystems, Foster City, CA) for real-time qPCR analysis. Thermal cycling parameters 
used consisted of: a hold stage at 50°C for 2 minutes; polymerase activation hold at 95°C 
for 20 seconds; PCR stage with step 1 at 95°C for 1 second followed by step 2 at 60°C 
for 20 seconds for 40 cycles. Replicate CT values were averaged and used for relative 
quantification using the 2−ΔΔCT method (Livak and Schmittgen, 2001). 
3.3.6 Analysis of Longissimus dorsi Immunohistochemistry 
 For each sample, the LM tissue embedded in OCT molds was sectioned into two-
10 μm cryosections via CRYOSTAR NX50 (Thermo Scientific, Waltham, MA), and 
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collected on positively charged SUPERFROST™ PLUS microscope slides (Thermo 
scientific, Waltham, MA). For immunodetection, nonspecific antigen binding sites were 
inhibited by incubating cryosections in 100 μl of blocking solution which consisted of 
5% horse serum (GE healthcare life sciences, Marlborough, MA) and 0.2% Triton-X-100 
(Acros Organics, Morris, NJ) in phosphate-buffered saline (PBS) for 30 minutes. Next, 
the blocking solution was removed via pipetting and cryosections were incubated with 
100 μl of the following antibodies at 4°C: 1:500 Dystrophin (Thermo Scientific, 
Waltham, MA), 1:10 supernatant myosin heavy chain, slow, IgG2b (BA-D5; 
Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA), 1:10 
hybridoma cell supernatant, IgG1 (PAX7; Developmental Studies Hybridoma Bank). 
After incubating for 1 hour, then primary antibodies were removed via pipetting, and the 
sections were washed 3 times for 5 minutes each with PBS. Next, the sections were 
incubated with 100 μl of secondary antibodies (1:1000) for 30 minutes: Alexa Fluor 488 
goat anti-mouse H&L (CAT # A-21121; Invitrogen, Carlsbad, CA), Alexa Fluor 594 goat 
anti-rabbit H&L (CAT # A-11012), Alexa Fluor 633 goat anti-mouse H&L (CAT # A-
21146), and Hoescht (CAT # 33342; Thermo Scientific, Waltham, MA). Secondary anti-
bodies were then removed via pipetting, and sections were washed 3 times for 5 minutes 
each. A small amount of glycerol in PBS (9:1) was applied to each section and cover-
slipped for imaging. Cryosections were imaged and captured using an EVOS® 
microscope (AMAFD1000; Life Technologies, Carlsbad, CA) with 20x magnification. 
Five representative photomicrographs were captured with a minimum of 500 fibers 
analyzed for each individual animal. Images captured with the EVOS® consisted of: GFP 
light cube (Alexa Fluor 488), Texas Red light cube (Alexa Fluor 594), Cy5 light cube 
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(Alexa Fluor 633), DAPI light cube (Hoescht 33342). Then the images were analyzed 
using ImageJ (https://imagej.nih.gov/ij/download.html). Total number of primary 
myofibers, secondary myofibers, primary myofiber cross-sectional area (CSA; μm2), 
secondary myofiber CSA (μm2), total number of nuclei, and total number PAX7 activated 
nuclei were collected and recorded. Calculations included: total primary to secondary 
myofiber ratio (number of primary myofibers/number of secondary myofibers), total 
PAX7 activated nuclei to total nuclei ratio (number of PAX7 nuclei/number nuclei), total 
nuclei to myofiber ratio (number of nuclei/number of myofibers), average primary 
myofiber CSA, and average secondary myofiber CSA. 
3.3.7 Statistical Analysis 
Gene expression, fatty acid analysis, immunohistochemistry, and LM 
morphometrics were analyzed using MIXED procedure of the Statistical Analysis System 
(SAS software version 9.4, SAS Institute, Cary, NC, USA). Where the model statement 
included: treatment, fetal sex, and their respective interactions. Data found to be 
nonnormally distributed were tested using the Wilcoxon rank sum test. Least square 
means and standard error of the means were reported. Pairwise comparisons between the 
least squares means of the treatment factor levels were computed using the PDIFF option 
of the LSMEANS statement. Statistical significance was determined at P < 0.05, and P-




3.4.1 Fatty Acid Analysis 
Total SFA did not differ (P > 0.05) in fetal samples: umbilical artery plasma, 
umbilical vein plasma, fetal trunk plasma, and PR fat from fetuses born from MEL or 
CON dams (Tables 3.4-3.11; Figures 3.1-3.4). Total SFA did not differ (P > 0.05) in 
maternal plasma between MEL and CON dams (Tables 3.12, 3.13; Figures 3.5). 
Individual SFA did not differ (P > 0.05) in fetal samples: umbilical artery plasma, 
umbilical vein plasma, fetal trunk plasma, and PR fat from fetuses born from MEL or 
CON dams (Tables 3.4-3.11). Individual SFA did not differ (P > 0.05) in maternal 
plasma from MEL treated dams compared to CON (Tables 3.12, 3.13). 
Total MUFA did not differ (P > 0.05) in fetal samples: umbilical artery plasma, 
fetal trunk plasma, and PR fat from fetuses born from MEL or CON dams (Tables 3.4-
3.11; Figures 3.1-3.4). However, maternal MEL supplementation tended to decrease (P = 
0.09) total MUFA percentage in umbilical vein plasma from fetuses born from MEL 
compared to CON dams (Table 3.7). Total MUFA did not differ (P > 0.05) in maternal 
plasma between MEL and CON dams (Tables 3.12, 3.13; Figures 3.5). Individual MUFA 
did not differ (P > 0.05) in fetal samples: umbilical artery plasma, umbilical vein plasma, 
fetal trunk plasma, and PR fat from fetuses born from MEL or CON dams (Tables 3.4-
3.11); except for Palmitoleic acid (16:1n-7) in fetal trunk plasma, which tended to be 
decreased (P = 0.07) in calves from MEL supplemented dams compared to CON (Table 
3.10). Individual MUFA did not differ (P > 0.05) in maternal plasma between MEL and 
CON dams (Tables 3.12, 3.13). 
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Total PUFA did not differ (P > 0.05) in fetal samples: umbilical artery plasma, 
umbilical vein plasma, fetal trunk plasma, and PR fat from fetuses born from MEL or 
CON dams (Tables 3.4-3.11; Figures 3.1-3.4). Total PUFA did not differ (P > 0.05) in 
maternal plasma between MEL and CON dams (Tables 3.12, 3.13; Figures 3.5). 
Individual PUFA did not differ (P > 0.05) in fetal samples: umbilical artery plasma, 
umbilical vein plasma, fetal trunk plasma, and PR fat from fetuses born from MEL or 
CON dams (Tables 3.4-3.11); except for Docosahexaenoic acid (22:6) in umbilical vein 
plasma and trunk plasma, which tended to be increased (P = 0.08) and (P = 0.06) 
respectively, in calves from MEL supplemented dams compared to CON (Tables 3.6, 3.7, 
3.11). Individual PUFA did not differ (P > 0.05) in maternal plasma between MEL and 
CON dams (Tables 3.12, 3.13). 
3.4.2 Fetal Morphometric Analysis 
Fetal body weight did not differ (P > 0.05) between fetuses from MEL dams 
compared to CON dams (Table 3.14; Figure 3.6). Fetal LM circumference and PR weight 
morphometrics did not differ (P > 0.05) between fetuses from MEL dams compared to 
CON dams (Table 3.14; Figures 3.8, 3.10). Fetal LM weight tended to increase (P = 0.10) 
and fetal LM length tended to increase (P = 0.07) between fetuses born from MEL 
compared to CON dams (Table 3.14; Figures 3.7, 3.9).  
3.4.3 Fetal Longissimus dorsi Relative Gene Expression Analysis 
Fetal LM relative gene expression did not differ (P > 0.05) in the following: 
IGF1, IGF1R, IGF2, IGF2R, BMP, LOX, Myf5, MyoG, MyoD, CEBPA, SCD, PPARg, 
or PNPLA2 between fetuses from MEL compared to CON dams (Tables 3.15, 3.16; 
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Figures 3.11-3.15, 3.17, 3.19-3.25); except for CYS and AMPK, which were increased (P 
= 0.02) and (P = 0.03) respectively, between fetuses born from MEL compared to CON 
dams (Table 3.15; Figures 3.16, 3.18). 
3.4.4 Fetal Perirenal Fat Relative Gene Expression Analysis 
Fetal PR relative gene expression did not differ (P > 0.05) in UCP1, PNPLA2, or 
IGF1R between fetuses from MEL compared to CON dams (Table 3.17; Figures 3.26, 
3.31, 3.33). However, maternal treatment of MEL resulted in calves with decreased 
relative gene expression in the following: ADIPOQ (P = 0.01), CEBPA (P = 0.03), 
PPARg (P = 0.04), SCD (P = 0.02), and IGF1 (P = 0.01) compared to calves from CON 
dams (Table 3.17; Figures 3.27-3.30, 3.32). Also, relative gene expression of IGF2 
tended to be decreased (P = 0.09) between fetuses from MEL compared to CON dams 
(Table 3.17; Figure 3.34). 
3.4.5 Fetal Longissimus dorsi IHC Analysis 
Fetal IHC did not differ (P > 0.05) in LM ratio of primary:secondary fibers 
(Prime:Sec), number of nuclei to muscle fiber number ratio (Nuclei:Fiber), primary 
muscle fiber CSA (Prime CSA), or secondary muscle fiber CSA (Sec CSA) between 
fetuses born from MEL compared to CON dams (Table 3.18; Figures 3.35, 3.37-3.39); 
except for the ratio of Pax7 activated nuclei to total nuclei (PAX7:Nuclei) which tended 
to increase (P = 0.07) between fetuses born from MEL compared to CON dams (Table 




 In the present study, there was no difference in fetal body weight between calves 
from MEL treated dams compared to CON dams. This supports the findings of Brockus 
and colleagues, as they found no difference in birth weight of Holstein calves from dams 
treated with MEL or CON (2016a). The authors found this interesting as they also 
reported finding a 25% increase in total uterine artery blood flow in Holstein heifers 
treated with MEL compared to CON (Brockus et al., 2016b). This observed increase in 
uterine artery blood flow lead them to expect an increase in birth weight of offspring, as 
reduced blood flow in compromised pregnancies results in lower birth weights (Thureen 
et al., 1992; Reynolds and Redmer, 1995; Ferrazzi et al., 2000; Rigano et al., 2001; 
Wallace et al., 2002; Konje et al., 2003; Regnault et al., 2003; Kwon et al., 2004; 
Reynolds et al., 2005; Vonnahme et al., 2013; Eifert et al., 2015). However, at weeks 8 
and 9 of age, the Holstein calves from MEL treated dams had increased body weights 
compared to that of calves from CON dams (Brockus et al., 2016a). The authors believed 
that MEL supplementation to Holstein dams during late gestation may have caused a 
programmed response leading to a change to fetal skeletal muscle development that 
potentially contributed to the increased weight gain (Brockus et al., 2016a).  
 To investigate the effects of MEL supplementation on skeletal muscle, the entire 
fetal LM muscle was collected to look at different morphometric measurements 
consisting of weight, circumference, and length. Maternal supplementation of MEL 
during late gestation resulted in fetal LM tending to weigh more and be longer than that 
of calves from CON treated dams. Upon IHC analysis, fetal LM of calves from dams 
treated with MEL had a tendency for increased PAX7 activated nuclei to total nuclei 
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ratio. The activation of PAX7 is required for fetal myoblast formation as PAX7+ 
progenitor cells act as a foundation and give rise to myogenic cells necessary for fetal 
skeletal muscle accretion (Hutcheson et al., 2009). This tendency for increased PAX7 
activation in fetal LM may explain the observed tendency for increased LM weight and 
length. To investigate further, fetal LM tissue was also collected for relative gene 
expression of genes responsible for myogenesis, adipogenesis, and fibrogenesis, as well 
as genes responsible for muscle metabolism.  
 Skeletal muscle is a heterogenous tissue comprised of myocytes, adipocyte, and 
fibrocytes with the overall ratio and distribution of these cells determining muscle 
composition, product yield, and meat quality. This lead to our decision to not only look at 
genes responsible for myogenesis, but adipogenic and fibrogenic genes as well (Tables 
3.1-3.3). Maternal supplementation of MEL during late gestation led to no difference in 
the examined myogenic and adipogenic genes. However, MEL supplementation lead to 
calves with increased CYS relative gene expression. A study conducted by Gonzalez et 
al. (2013) with nutrient restricting cross-bred cows from day 30 of gestation till day 85 of 
gestation resulted in fetuses with a tendency for CYS to be increased compared to fetuses 
from non-restricted dams. They concluded that the increase would result in increased 
numbers of connective tissue fibroblasts (Gonzalez et al., 2013) 
 Muscle accretion is not only influenced by myogenic genes, but also genes that 
influence muscle metabolism which provides the necessary energy for muscle growth. 
Maternal supplementation of MEL during late gestation led to an increase in AMPK 
relative gene expression in fetal LM compared to that of calves from CON dams. 
Increased AMPK activity has been shown to increase glucose uptake, fatty acid 
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oxidation, and mitochondrial biogenesis by increasing the expression of genes 
responsible for these metabolic pathways (Jager et al., 2007). The ability for AMPK to 
increase glucose uptake is very important as skeletal muscle is responsible for 65% of 
fetal glucose disposal (Hay, 2003). In an AMPK knockout study using mice, researchers 
found that AMPK modulates several metabolic genes within muscle tissue and could be a 
candidate for transmitting exercise signals to the nucleus (Jorgensen et al., 2006). 
Therefore, the increased AMPK expression could potentially lead to increased glucose 
uptake and cell recovery in skeletal muscle in cattle and decrease triglycerides within 
skeletal muscle resulting in leaner beef. 
 In addition to investigating the effects of MEL on skeletal muscle, we also looked 
at blood plasma and PR adipose tissue. The effects of MEL on decreasing adiposity is 
well documented in rodents (Elliott et al., 1989; Puchalski et al., 2003; Raskind et al., 
2007; Korhonen et al., 2008). Maternal supplementation of MEL during late gestation 
resulted in no difference in fetal PR weight of calves between treatment groups. This is 
surprising as studies with sheep (Seron-Ferre et al., 2015) and hamsters (Heldmaier and 
Hoffmann, 1974) have shown MEL to increase BAT growth. The absence of BAT 
accretion in the calves may potentially be due to MEL decreasing relative gene 
expression of adipogenic genes: ADIPOQ, CEBPA, PPARg, and SCD.  
Studies on the effects of ADIPOQ have shown increased ADIPOQ expression to reduce 
plasma glucose, reverse insulin resistance, and decrease triglyceride content of adipose 
tissue (Yamauchi et al., 2001; Nishizawa et al., 2002; Diez and Iglesias, 2003). Yamauchi 
et al. (2001) suggested that ADIPOQ may be partially regulated by PPARg due to their 
findings of no detectable ADIPOQ expression in adipose depleted mice which was 
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achieved by a severe reduction in PPARg activity. Stimulation of PPARg not only 
mediates adipose accretion, but adipogenesis during fetal development. Permanent 
differentiation of mesenchymal stem cells into adipocytes requires self-reinforcing 
regulation of transcription factors CEBPA and PPARg (Clarke et al., 1997; Wu et al., 
1999). When CEBPA is induced and binds to the promoter of PPARg, it activates the 
expression of PPARg which further stimulates the expression of CEBPA (Clarke et al., 
1997; Wu et al., 1999). With the activation and expression of PPARg, terminal 
adipogenic differentiation is achieved through the induction of many genes that are 
important for triglyceride uptake and storage (Frohnert et al., 1999; Rosen and 
MacDougald, 2006). Decreased expression of CEBPA and PPARg causes decrease fat 
deposition (Tontonoz et al., 1994; Forman et al., 1995; Barak et al., 1999; Lan et al., 
2013), with CEBPA also being attributed as a regulator for BAT differentiation 
(Armengol et al., 2012). The stimulation of SCD plays an important role in adipose 
development through mediating MUFA synthesis, as it is the rate-limiting enzyme for 
biosynthesis (Ntambi et al., 2002). Mice with SCD knocked out have shown to exhibit 
reduced triglyceride synthesis and storage, resulting in decreased adiposity and mice had 
increased insulin sensitivity (Ntambi et al., 2002).  
 After observing decreases in genes responsible for adipogenic gene express in PR 
adipose tissue and the increase of metabolic gene AMPK in LM muscle tissue, we 
decided to look at metabolic genes in PR adipose tissue as well. Maternal 
supplementation of MEL during late gestation resulted in decreased IGF1 relative gene 
expression and tended to decrease IGF2 in PR adipose tissue. The effects of IGF2 is 
mainly responsible for fetal growth and IGF1 is mainly responsible for postnatal growth 
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and development (Florini et al., 1991; Haig and Graham, 1991; Braxton et al., 1993; Bass 
et al., 1999; Le Roith et al., 2001; Gluckman and Pinal, 2003; Gonzalez et al., 2013). The 
stimulation of IGF1 has shown to play an important role in adipogenesis by increasing 
the recruitment of cells thereby increasing adipose cell numbers (Hu et al., 2015), while 
IGF2 has been suggested to play a role in preventing terminal adipocyte differentiation 
(Gardan et al., 2008; Kleiman et al., 2013). 
 In Summary, maternal supplementation of MEL during late gestation does impact 
LM muscle and PR adipose tissue development of fetal calves by d 240 of gestation. The 
increase in metabolic associated genes within the LM promoting lipid oxidation and 
energy uptake paired with the decreased adipogenic gene expression could lead to calves 
with less adiposity and improved muscle accretion. Future analysis of fetal PR adipose 
morphology via IHC will be needed to determine the extent of physical changes to size 
and/or number of adipocytes. Also, further research into the effects of maternal 
supplementation of MEL during late gestation on postnatal calves will be needed to 









Table 3.1 Accession, sequences, amplicon length, and efficiency of primers used for 
QuantiNovaTM SYBR® Green real-time PCR quantification of Longissimus 
dorsi gene expression. 
1 IGF1 = insulin-like growth factor 1, IGF1R = IGF1 receptor, IGF2 = insulin-like growth 
factor 2, IGF2R = IGF2 receptor, BMP = bone morphogenetic protein, CYS = cystatin, 

























































CACCTTGGTGTTTGGATTTCTG 80 0.99 
Beta 
Actin 
NM_173979  GTCGACACCGCAACCAGTT  AAGCCGGCCTTGCACAT  85 0.94 
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Table 3.2 Assays, accession, amplicon length, and efficiency of primers used for 
TaqMan® real-time PCR quantification of Longissimus dorsi gene 
expression. 
Gene1 Assay ID Accession  Amplicon Size Efficiency 
Beta Actin Bt03279174_g1  NP_776404 141 0.96 
Myf5 Bt03223134_m1  NP_776541 98 0.95 
MyoG Bt03258928_m1 NP_001104795.1 96 0.96 
MyoD Bt03244740_m1 NP_001035568.2 84 0.95 
CEBPA Bt03224529_s1  NP_789741 124 0.99 
SCD Bt04307478_m1 NP_776384.3 89 0.97 
PPARg Bt03217547_m1  NP_851367.1 85 0.93 
PNPLA2 Bt03234128_m1 NP_001039470.1 77 0.98 
1 Myf5 = myogenic factor 5, MyoG = myogenin, MyoD = myogenic differentiation 1, 
CEBPA = CCAAT enhancer binding protein alpha, SCD = stearoyl-CoA desaturase, 
PPARg = peroxisome proliferator activated receptor gamma, PNPLA2 = patatin-like 
















Table 3.3 Assays, accession, amplicon length, and efficiency of primers used for 
TaqMan® real-time PCR quantification of perirenal adipose tissue gene 
expression. 
Gene1 Assay ID Accession  Amplicon Size Efficiency 
Beta Actin Bt03279174_g1  NP_776404 141 0.97 
UCP1 Bt04301238_m1 NM_001166528.1 74 0.92 
ADIPOQ Bt03292341_s1 NM_174742.2 121 0.94 
CEBPA Bt03224529_s1  NP_789741 124 0.92 
PPARG Bt03272016_m1 NM_001101152.2 65 0.94 
SCD Bt04307478_m1 NP_776384.3 89 0.95 
PNPLA2 Bt03234128_m1 NP_001039470.1 77 0.99 
IGF2 Bt03259225_m1 NP_776512.2 54 0.95 
IGF1 Bt03252282_m1 NM_001077828.1 65 0.99 
IGF1R Bt03649217_m1  NP_001231541.1 70 0.93 
1 UCP1 = uncoupling protein 1, ADIPOQ = adiponectin, CEBPA = CCAAT 
enhancer binding protein alpha, PPARg = peroxisome proliferator activated 
receptor gamma, SCD = stearoyl-CoA desaturase, PNPLA2 = patatin-like 
phospholipase domain containing 2, IGF2 = insulin-like growth factor 2, IGF1 = 















Table 3.4 Fetal umbilical artery composition of saturated (SFA), monounsaturated 
(MUFA), and polyunsaturated fatty acids (PUFA) of calves CON (n=6), 
MEL (n=6).  
 Fetal Umbilical Artery (mg/ml) 
 Treatment 
Fatty Acid CON MEL SEM P Value 
SFA 0.2812 0.2665 0.0221 0.52 
15:0 0.0096 0.0077 0.0017 0.30 
16:0 0.1696 0.1628 0.0133 0.62 
17:0 0.0118 0.0082 0.0035 0.32 
18:0 0.0900 0.0883 0.0065 0.80 
MUFA 0.1818 0.1727 0.0153 0.57 
14:1n-5 0.0062 0.0035 0.0037 0.48 
16:1n-7 0.0306 0.0285 0.0026 0.44 
17:1n-8 0.0096 0.0078 0.0021 0.43 
18:1n-trans 0.0010 0.0000 0.0009 0.30 
18:1n-9 cis 0.1342 0.1330 0.0121 0.92 
PUFA 0.1044 0.0940 0.0131 0.45 
18:2n-6 0.0474 0.0467 0.0033 0.83 
18:3n-3 0.0142 0.0143 0.0051 0.98 
20:3n-6 0.0106 0.0070 0.0020 0.11 
20:4n-6 0.0248 0.0217 0.0049 0.54 
20:5n-3 0.0062 0.0047 0.0019 0.44 
22:6 0.0012 0.0000 0.0011 0.30 
TOTAL 0.5676 0.5333 0.0462 0.48 
SI* 0.9860 1.0067 0.0434 0.65 
DI** 0.3880 0.3933 0.0058 0.38 
*SI = saturation index (total SFA/total MUFA + total PUFA) 








Table 3.5 Fetal umbilical artery composition in percent of saturated (SFA), 
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA) of 
calves CON (n=6), MEL (n=6).  
 Fetal Umbilical Artery1 (%) 
 Treatment 
Fatty Acid CON MEL SEM P Value 
SFA 49.5600 50.1083 1.0867 0.63 
15:0 1.6380 1.4100 0.2492 0.38 
16:0 29.9420 30.5733 0.5802 0.30 
17:0 2.0180 1.5550 0.5655 0.43 
18:0 15.9660 16.5717 0.7104 0.42 
MUFA 32.0600 32.3733 0.7948 0.70 
14:1n-5 1.0880 0.5900 0.6531 0.47 
16:1n-7 5.3740 5.3750 0.1825 1.00 
17:1n-8 1.6580 1.4683 0.2987 0.54 
18:1n-trans 0.2220 0.0000 0.2004 0.30 
18:1n-9 cis 23.7140 24.9383 1.0539 0.28 
PUFA 18.3780 17.5183 1.6326 0.61 
18:2n-6 8.3640 8.7633 0.4156 0.36 
18:3n-3 2.4280 2.5850 0.8981 0.87 
20:3n-6 1.8860 1.2967 0.3636 0.14 
20:4n-6 4.3240 3.9933 0.7190 0.66 
20:5n-3 1.1780 0.8767 0.3998 0.47 
22:6 0.2000 0.0000 0.1805 0.30 











Table 3.6 Fetal umbilical vein composition of saturated (SFA), monounsaturated 
(MUFA), and polyunsaturated fatty acids (PUFA) of calves CON (n=6), 
MEL (n=6).  
 Fetal Umbilical Vein (mg/ml) 
 Treatment 
Fatty Acid CON MEL SEM P Value 
SFA 0.2783 0.2872 0.0207 0.68 
15:0 0.0070 0.0127 0.0036 0.16 
16:0 0.1680 0.1698 0.0112 0.87 
17:0 0.0070 0.0113 0.0037 0.28 
18:0 0.0963 0.0935 0.0087 0.75 
MUFA 0.1990 0.1933 0.0214 0.80 
14:1n-5 0.0020 0.0020 0.0013 1.00 
16:1n-7 0.0283 0.0282 0.0023 0.94 
17:1n-8 0.0090 0.0110 0.0036 0.59 
18:1n-trans 0.0260 0.0303 0.0265 0.87 
18:1n-9 cis 0.1340 0.1217 0.0237 0.62 
PUFA 0.0967 0.1357 0.0235 0.14 
18:2n-6 0.0453 0.0480 0.0022 0.26 
18:3n-3 0.0157 0.0165 0.0007 0.25 
20:3n-6 0.0077 0.0080 0.0018 0.86 
20:4n-6 0.0237 0.0232 0.0050 0.92 
20:5n-3 0.0040 0.0042 0.0015 0.91 
22:6 0.0000x 0.0362y 0.0176 0.08 
TOTAL 0.5743 0.6165 0.0548 0.47 
SI* 0.9500 0.8850 0.0696 0.38 
DI** 0.3767 0.3617 0.0307 0.64 
x–y Means within a row without common superscript represent tendencies (P ≥ 0.05 and P 
≤ 0.10)  
*SI = saturation index (total SFA/total MUFA + total PUFA) 








Table 3.7 Fetal umbilical vein composition in percent of saturated (SFA), 
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA) of 
calves CON (n=6), MEL (n=6).  
 Fetal Umbilical Vein1 (%) 
 Treatment 
Fatty Acid CON MEL SEM P Value 
SFA 48.6700 46.7883 1.8450 0.34 
15:0 1.2367 2.0233 0.5595 0.20 
16:0 29.4500 27.6833 1.4001 0.25 
17:0 1.2067 1.8033 0.5462 0.31 
18:0 16.7700 15.2817 0.9339 0.16 
MUFA 34.4033x 31.4650y 1.5222 0.09 
14:1n-5 0.2833 0.3417 0.2025 0.78 
16:1n-7 4.9800 4.6067 0.3386 0.31 
17:1n-8 1.5133 1.7700 0.5536 0.66 
18:1n-trans 4.1933 4.7467 4.1065 0.90 
18:1n-9 cis 23.4300 19.9983 3.8784 0.41 
PUFA 16.9233 21.7467 2.8208 0.13 
18:2n-6 8.0867 7.8067 0.6111 0.66 
18:3n-3 2.8300 2.6983 0.2931 0.67 
20:3n-6 1.3467 1.2933 0.2404 0.83 
20:4n-6 3.9433 3.7133 0.5807 0.70 
20:5n-3 0.7167 0.6700 0.2422 0.85 
22:6 0.0000x 5.5667y 2.6797 0.08 
x–y Means within a row without common superscript represent tendencies (P ≥ 0.05 and P 
≤ 0.10)  










Table 3.8 Fetal perirenal fat composition of saturated (SFA), monounsaturated 
(MUFA), and polyunsaturated fatty acids (PUFA) of calves CON (n=6), 
MEL (n=6).  
 Fetal Perirenal fat (mg/ml) 
 Treatment 
Fatty Acid CON MEL SEM P Value 
SFA 285.4800 278.6900 22.1971 0.77 
8:0 0.1760 0.1464 0.0301 0.35 
10:0 0.4026 0.3177 0.0615 0.20 
12:0 0.4292 0.3540 0.0835 0.39 
14:0 16.6552 15.1861 3.1679 0.65 
15:0 0.2430 0.2334 0.0211 0.66 
16:0 203.4000 201.9400 14.8767 0.92 
18:0 64.1806 60.5114 5.9566 0.55 
MUFA 265.8800 280.2300 12.1603 0.27 
14:1n-5 5.1440 5.4031 0.7405 0.73 
16:1n-7 40.2998 39.5599 3.3678 0.83 
17:1n-8 1.4928 1.5276 0.1284 0.79 
18:1n-trans 1.0998 1.1584 0.0493 0.26 
18:1n-9 cis 215.5100 230.1100 12.3752 0.27 
20:1n-9 2.0660 2.2594 0.3186 0.56 
24:1n-9 0.2640 0.2110 0.0456 0.27 
PUFA 4.7594 4.4243 0.5140 0.53 
18:2n-6 1.8620 1.7579 0.1472 0.50 
18:3n-6 0.0852 0.0720 0.0128 0.33 
18:3n-3 0.8818 0.9223 0.0651 0.55 
20:2 0.1144 0.1237 0.0292 0.76 
20:3n-6 0.3958 0.3194 0.0899 0.42 
20:4n-6 0.9070 0.7610 0.1433 0.33 
20:5n-3 0.0876 0.1176 0.0233 0.23 
22:6 0.4256 0.3507 0.0991 0.47 
TOTAL 556.1200 563.3500 23.2497 0.76 
SI* 1.0588 0.9879 0.1031 0.51 
DI** 0.4902 0.5074 0.0235 0.48 
*SI = saturation index (total SFA/total MUFA + total PUFA) 





Table 3.9 Fetal perirenal fat composition in percent of saturated (SFA), 
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA) of 
calves CON (n=6), MEL (n=6).  
 Fetal Perirenal fat1 (%) 
 Treatment 
Fatty Acid CON MEL SEM P Value 
SFA 51.1814 49.3514 2.4252 0.47 
8:0 0.0314 0.0260 0.0055 0.35 
10:0 0.0716 0.0566 0.0101 0.17 
12:0 0.0764 0.0627 0.0137 0.34 
14:0 2.9674 2.6827 0.4982 0.58 
15:0 0.0432 0.0417 0.0034 0.67 
16:0 36.4966 35.7701 1.5633 0.65 
18:0 11.4946 10.7116 0.7826 0.34 
MUFA 47.9658 49.8613 2.4136 0.45 
14:1n-5 0.9236 0.9616 0.1248 0.77 
16:1n-7 7.2716 7.0387 0.6347 0.72 
17:1n-8 0.2674 0.2726 0.0220 0.82 
18:1n-trans 0.1978 0.2064 0.0092 0.37 
18:1n-9 cis 38.8826 40.9404 2.3259 0.40 
20:1n-9 0.3744 0.4039 0.0628 0.65 
24:1n-9 0.0480 0.0374 0.0087 0.25 
PUFA 0.8528 0.7873 0.0850 0.46 
18:2n-6 0.3338 0.3134 0.0241 0.42 
18:3n-6 0.0154 0.0127 0.0022 0.25 
18:3n-3 0.1588 0.1641 0.0123 0.67 
20:2 0.0204 0.0219 0.0048 0.77 
20:3n-6 0.0704 0.0566 0.0152 0.38 
20:4n-6 0.1622 0.1351 0.0244 0.29 
20:5n-3 0.0158 0.0211 0.0044 0.25 
22:6 0.0760 0.0621 0.0170 0.44 








Table 3.10 Fetal trunk plasma composition of saturated (SFA), monounsaturated 
(MUFA), and polyunsaturated fatty acids (PUFA) of calves CON (n=6), 
MEL (n=6).  
 Fetal Plasma (mg/ml) 
 Treatment 
Fatty Acid CON MEL SEM P Value 
SFA 0.3564 0.2479 0.0920 0.27 
15:0 0.0090 0.0074 0.0039 0.70 
16:0 0.1892 0.1497 0.0308 0.23 
17:0 0.0088 0.0044 0.0038 0.28 
18:0 0.1498 0.0863 0.0543 0.27 
MUFA 0.2170 0.1573 0.0452 0.22 
14:1n-5 0.0006 0.0000 0.0005 0.26 
16:1n-7 0.0294x 0.0241y 0.0026 0.07 
17:1n-8 0.0084 0.0063 0.0022 0.36 
18:1n-trans 0.0120 0.0001 0.0099 0.26 
18:1n-9 cis 0.1662 0.1264 0.0303 0.22 
PUFA 0.1818 0.0840 0.0816 0.26 
18:2n-6 0.1216 0.0447 0.0641 0.26 
18:3n-3 0.0014 0.0000 0.0012 0.26 
20:3n-6 0.0116 0.0067 0.0044 0.29 
20:4n-6 0.0294 0.0184 0.0080 0.20 
20:5n-3 0.0096 0.0039 0.0057 0.34 
22:6 0.0084 0.0106 0.0018 0.27 
TOTAL 0.7554 0.4894 0.2184 0.25 
SI* 0.9600 1.0286 0.0430 0.14 
DI** 0.3800 0.3871 0.0130 0.60 
x–y Means within a row without common superscript represent tendencies (P ≥ 0.05 and P 
≤ 0.10)  
*SI = saturation index (total SFA/total MUFA + total PUFA) 








Table 3.11 Fetal trunk plasma composition in percent of saturated (SFA), 
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA) of 
calves CON (n=6), MEL (n=6).  
 Fetal Plasma1 (%) 
 Treatment 
Fatty Acid CON MEL SEM P Value 
SFA 48.8320 50.6714 1.1309 0.13 
15:0 1.0620 1.4929 0.3533 0.25 
16:0 28.5280 30.5771 2.1035 0.35 
17:0 0.9900 0.9314 0.1355 0.67 
18:0 18.2540 17.6700 1.0046 0.57 
MUFA 31.2480 32.1543 1.5655 0.58 
14:1n-5 0.0480 0.0071 0.0279 0.17 
16:1n-7 4.7780 4.9614 0.5412 0.74 
17:1n-8 1.2060 1.2829 0.1597 0.64 
18:1n-trans 0.6680 0.0343 0.5543 0.28 
18:1n-9 cis 24.5440 25.8657 1.5711 0.42 
PUFA 19.9180 17.1771 2.5486 0.31 
18:2n-6 11.9920 9.1643 2.4893 0.28 
18:3n-3 0.2560 0.0000 0.2120 0.26 
20:3n-6 1.4100 1.3271 0.1756 0.65 
20:4n-6 3.9900 3.7629 0.4484 0.62 
20:5n-3 0.8860 0.7786 0.2673 0.70 
22:6 1.3820x 2.1400y 0.3517 0.06 
x–y Means within a row without common superscript represent tendencies (P ≥ 0.05 and P 
≤ 0.10)  









Table 3.12 Maternal plasma composition of saturated (SFA), monounsaturated 
(MUFA), and polyunsaturated fatty acids (PUFA) of calves CON (n=6), 
MEL (n=6).  
 Maternal Plasma (mg/ml) 
 Treatment 
Fatty Acid CON MEL SEM P Value 
SFA 0.5550 0.5570 0.0581 0.97 
15:0 0.0196 0.0179 0.0019 0.38 
16:0 0.2514 0.2473 0.0188 0.83 
17:0 0.0182 0.0174 0.0023 0.74 
18:0 0.2664 0.2746 0.0361 0.83 
MUFA 0.3140 0.3093 0.0273 0.87 
14:1n-5 0.0186 0.0181 0.0021 0.83 
16:1n-7 0.0314 0.0300 0.0025 0.59 
17:1n-8 0.0110 0.0107 0.0016 0.86 
18:1n-trans 0.0372 0.0386 0.0077 0.86 
18:1n-9 cis 0.2160 0.2123 0.0186 0.85 
PUFA 0.5496 0.5140 0.0500 0.49 
18:2n-6 0.3038 0.2840 0.0313 0.54 
18:3n-3 0.1486 0.1429 0.0148 0.71 
20:3n-6 0.0246 0.0206 0.0027 0.16 
20:4n-6 0.0468 0.0389 0.0061 0.22 
20:5n-3 0.0242 0.0239 0.0018 0.86 
22:6 0.0016 0.0040 0.0016 0.16 
TOTAL 1.4186 1.3803 0.1278 0.77 
SI* 0.6420 0.6743 0.0345 0.37 
DI** 0.3280 0.3186 0.0133 0.49 
*SI = saturation index (total SFA/total MUFA + total PUFA) 









Table 3.13 Maternal plasma composition in percent of saturated (SFA), 
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA) of 
calves CON (n=6), MEL (n=6).  
 Maternal Plasma1 (%) 
 Treatment 
Fatty Acid CON MEL SEM P Value 
SFA 39.0940 40.2229 1.1765 0.36 
15:0 1.3820 1.2843 0.0933 0.32 
16:0 17.8360 17.9429 0.4434 0.81 
17:0 1.2640 1.2600 0.0868 0.96 
18:0 18.6100 19.7329 1.0756 0.32 
MUFA 22.2260 22.4186 0.7255 0.80 
14:1n-5 1.3320 1.3014 0.1170 0.80 
16:1n-7 2.2240 2.1986 0.1545 0.87 
17:1n-8 0.7720 0.7643 0.0962 0.94 
18:1n-trans 2.5680 2.7400 0.4035 0.68 
18:1n-9 cis 15.3300 15.4186 0.7042 0.90 
PUFA 38.6820 37.3600 1.2863 0.33 
18:2n-6 21.3200 20.5829 0.8042 0.38 
18:3n-3 10.4720 10.4300 0.7707 0.96 
20:3n-6 1.7560 1.4914 0.1574 0.12 
20:4n-6 3.3240 2.8043 0.3413 0.16 
20:5n-3 1.7020 1.7600 0.1520 0.71 
22:6 0.1080 0.2900 0.1134 0.14 











Table 3.14 Fetal morphometrics with body weight (BW; kg) and Longissimus dorsi 
(LM) weight (kg), circumference (cm), and length (cm) of muscle and 
perirenal (PR) adipose tissue weight (kg) for calves CON (n=6), MEL 
(n=6).  
 Morphometric Measurements 
 Treatment 
Measurements CON MEL SEM P Value 
BW (kg) 24.0000 22.9000 1.9000 0.56 
LM Weight (kg) 0.2218x 0.2633y 0.0227 0.10 
LM Circumference (cm) 32.8833 38.5667 4.1250 0.21 
LM Length (cm) 10.0667x 11.4500y 0.6564 0.07 
PR Weight (kg) 0.0623 0.1667 0.0984 0.32 
x–y Means within a row without common superscript represent tendencies (P ≥ 0.05 and P 


















Table 3.15 QuantiNovaTM SYBR® Green real-time PCR quantification of Fetal 
Longissimus dorsi (LM) PCR relative expression of IGF1, IGF1R, IGF2, 
IGF2R, BMP, CYS, LOX, and AMPK of calves CON (n=6), MEL (n=6).  
 Longissimus dorsi PCR Relative Expression 
 Treatment 
Gene1 CON MEL SEM P Value 
IGF1 5.3333 7.6667 1.7847 0.23 
IGF1R 5.5000 7.5000 1.8359 0.31 
IGF2 5.5000 7.5000 1.5753 0.24 
IGF2R 5.6667 7.3333 1.6777 0.35 
BMP 5.6667 7.3333 1.8053 0.38 
CYS 4.3333a 8.6667b 1.4985 0.02 
LOX 5.5000 7.5000 1.7213 0.28 
AMPK 4.5000a 8.5000b 1.5516 0.03 
a–b Means within a row without common superscript differ (P < 0.05) 
1 IGF1 = insulin-like growth factor 1, IGF1R = IGF1 receptor, IGF2 = insulin-like growth 
factor 2, IGF2R = IGF2 receptor, CYS = cystatin, AMPK = adenosine monophosphate-















Table 3.16 TaqMan® real-time PCR quantification of Fetal Longissimus dorsi (LM) 
PCR relative expression of IGF1, IGF1R, IGF2, IGF2R, BMP, CYS, LOX, 
and AMPK of calves CON (n=6), MEL (n=6).  
 LM PCR Relative Expression 
 Treatment 
Gene1 CON MEL SEM P Value 
Myf5 6.4167 6.5833 1.9003 0.93 
MyoG 5.2500 7.7500 1.6429 0.17 
MyoD 6.0000 7.0000 1.7717 0.59 
CEBPA 5.2500 7.7500 1.8130 0.21 
SCD 5.8333 7.1667 1.9245 0.51 
PPARg 6.1667 6.8333 1.5986 0.69 
PNPLA2 5.4167 7.5833 1.6073 0.21 
1Myf5 = myogenic factor 5, MyoG = myogenin, MyoD = myogenic differentiation 1, 
CEBPA = CCAAT enhancer binding protein alpha, SCD = stearoyl-CoA desaturase, 
PPARg = peroxisome proliferator activated receptor gamma, PNPLA2 = patatin-like 
















Table 3.17 Fetal perirenal adipose tissue (PR) PCR relative expression of ADIPOQ, 
IGF1, and UCP1 of calves CON (n=6), MEL (n=6).  
 PR PCR Relative Expression 
 Treatment 
Gene1 CON MEL SEM P Value 
UCP1 7.0000 6.0000 1.9484 0.62 
ADIPOQ 8.8333a 4.1667b 1.3878 0.01 
CEBPA 8.1667a 4.8333b 1.2172 0.03 
PPARG 8.3333a 4.6667b 1.4530 0.04 
SCD 8.3333a 4.6667b 1.2247 0.02 
PNPLA2 7.8333 5.1667 1.7105 0.16 
IGF2 8.0000x 5.0000y 1.5694 0.09 
IGF1 8.6667a 4.3333b 1.2910 0.01 
IGF1R 7.3333 5.6667 1.6833 0.35 
a–b Means within a row without common superscript differ (P < 0.05) 
x–y Means within a row without common superscript represent tendencies (P ≥ 0.05 and P 
≤ 0.10)  
1 UCP1 = uncoupling protein 1, ADIPOQ = adiponectin, CEBPA = CCAAT enhancer 
binding protein alpha, PPARg = peroxisome proliferator activated receptor gamma, SCD 
= stearoyl-CoA desaturase, PNPLA2 = patatin-like phospholipase domain containing 2, 















Table 3.18 Fetal immunohistochemistry of Longissimus dorsi (LM) with number of 
primary to secondary fibers (Prime:Sec), number of PAX7 activated nuclei 
to total nuclei (PAX7:Nuclei), total number of nuclei to number of 
myofibers (Nuclei:Fiber ), and cross-sectional areas of primary and 
secondary fibers (Prime CSA; Sec CSA) of calves CON (n=6), MEL (n=6).  
 Longissimus dorsi Immunohistochemistry 
 Treatment 
Gene CON MEL SEM P Value 
Prime:Sec1 5.3645 6.1296 0.5060 0.17 
PAX7:Nuclei2 0.1285x 0.2042y 0.0356 0.07 
Nuclei:Fiber3  0.6716 0.5922 0.0592 0.22 
Prime CSA4 517.7500 535.4900 181.1200 0.92 
Sec CSA5 635.4700 469.1600 281.0800 0.57 
x–y Means within a row without common superscript represent tendencies (P ≥ 0.05 and P 
≤ 0.10)  
1 Ratio of primary to secondary myofibers (Primary fiber total/Secondary fiber total) 
2 Ratio of PAX7 activated nuclei to total nuclei (PAX7 total/Nuclei total) 
3 Ratio of nuclei total to number of total myofibers (Nuclei total/Myofiber total) 















Figure 3.1 Fetal umbilical artery composition of saturated (SFA), monounsaturated 
(MUFA), and polyunsaturated fatty acids (PUFA), in milligrams per 












Figure 3.2 Fetal umbilical vein composition of saturated (SFA), monounsaturated 
(MUFA), and polyunsaturated fatty acids (PUFA), in milligrams per 












Figure 3.3 Fetal perirenal fat composition of saturated (SFA), monounsaturated 
(MUFA), and polyunsaturated fatty acids (PUFA), in milligrams per 













Figure 3.4 Fetal trunk plasma composition of saturated (SFA), monounsaturated 
(MUFA), and polyunsaturated fatty acids (PUFA), in milligrams per 












Figure 3.5 Maternal plasma composition of saturated (SFA), monounsaturated 
(MUFA), and polyunsaturated fatty acids (PUFA), in milligrams per 













Figure 3.6 Body weight average from fetuses harvested from CON (n=6) vs. MEL 









Figure 3.7 Fetal Longissimus dorsi average weight (kg) from fetuses harvested from 
CON (n=6) vs. MEL (n=6) treated dams. x–y Means within a row without 


















Figure 3.8 Fetal Longissimus dorsi average circumference (cm) from fetuses 
harvested from CON (n=6) vs. MEL (n=6) treated dams. x–y Means within a 

















Figure 3.9 Fetal Longissimus dorsi average length (cm) from fetuses harvested from 
CON (n=6) vs. MEL (n=6) treated dams. x–y Means within a row without 































Figure 3.10 Fetal perirenal adipose tissue average weight (kg) from fetuses harvested 
























Figure 3.11 Relative expression (mRNA abundance) of Insulin-Like Growth factor 1 in 


















Figure 3.12 Relative expression (mRNA abundance) of Insulin-Like Growth factor 1 
receptor in Longissimus dorsi, from fetuses harvested from CON (n=6) vs. 

















Figure 3.13 Relative expression (mRNA abundance) of Insulin-Like Growth factor 2 in 


















Figure 3.14 Relative expression (mRNA abundance) of Insulin-Like Growth factor 2 
receptor in Longissimus dorsi, from fetuses harvested from CON (n=6) vs. 
















Figure 3.15 Relative expression (mRNA abundance) of bone morphogenetic protein in 
















Figure 3.16 Relative expression (mRNA abundance) of cystatin in Longissimus dorsi, 
from fetuses harvested from CON (n=6) vs. MEL (n=6) treated dams. a–b 


















Figure 3.17 Relative expression (mRNA abundance) of lysyl oxidase in Longissimus 

















Figure 3.18 Fetal Relative expression (mRNA abundance) of adenosine 
monophosphate-activated protein kinase-α in Longissimus dorsi, from 
fetuses harvested from CON (n=6) vs. MEL (n=6) treated dams. a–b Means 












Figure 3.19 Fetal Relative expression (mRNA abundance) of myogenic factor 5 in 
Longissimus dorsi, from fetuses harvested from CON (n=6) vs. MEL (n=6) 










Figure 3.20 Fetal Relative expression (mRNA abundance) of myogenin in Longissimus 











Figure 3.21 Fetal Relative expression (mRNA abundance) of myogenic differentiation 
1 in Longissimus dorsi, from fetuses harvested from CON (n=6) vs. MEL 










Figure 3.22 Fetal Relative expression (mRNA abundance) of CCAAT enhancer binding 
protein alpha in Longissimus dorsi, from fetuses harvested from CON 












Figure 3.23 Fetal Relative expression (mRNA abundance) of stearoyl-CoA desaturase 
in Longissimus dorsi, from fetuses harvested from CON (n=6) vs. MEL 












Figure 3.24 Fetal Relative expression (mRNA abundance) of peroxisome proliferator 
activated receptor gamma in Longissimus dorsi, from fetuses harvested 













Figure 3.25 Fetal Relative expression (mRNA abundance) of patatin-like phospholipase 
domain containing 2 in Longissimus dorsi, from fetuses harvested from 









Figure 3.26 Fetal Relative expression (mRNA abundance) of uncoupling protein 1 in 
perirenal adipose tissue, from fetuses harvested from CON (n=6) vs. MEL 









Figure 3.27 Fetal Relative expression (mRNA abundance) of adiponectin in perirenal 
adipose tissue, from fetuses harvested from CON (n=6) vs. MEL (n=6) 












Figure 3.28 Fetal Relative expression (mRNA abundance) of CCAAT enhancer binding 
protein alpha in perirenal adipose tissue, from fetuses harvested from CON 
(n=6) vs. MEL (n=6) treated dams. a-b Significance of means without 












Figure 3.29 Fetal Relative expression (mRNA abundance) of peroxisome proliferator 
activated receptor gamma in perirenal adipose tissue, from fetuses 
harvested from CON (n=6) vs. MEL (n=6) treated dams. a-b Significance of 












Figure 3.30 Fetal Relative expression (mRNA abundance) of stearoyl-CoA desaturase 
in perirenal adipose tissue, from fetuses harvested from CON (n=6) vs. 
MEL (n=6) treated dams. a-b Significance of means without common letters 










Figure 3.31 Fetal Relative expression (mRNA abundance) of patatin-like phospholipase 
domain containing 2 in perirenal adipose tissue, from fetuses harvested 








Figure 3.32 Fetal Relative expression (mRNA abundance) of insulin-like growth factor 
1 in perirenal adipose tissue, from fetuses harvested from CON (n=6) vs. 
MEL (n=6) treated dams. a-b Significance of means without common letters 













Figure 3.33 Fetal Relative expression (mRNA abundance) of insulin-like growth factor 
1 receptor in perirenal adipose tissue, from fetuses harvested from CON 










Figure 3.34 Fetal Relative expression (mRNA abundance) of insulin-like growth factor 
2 in perirenal adipose tissue, from fetuses harvested from CON (n=6) vs. 
MEL (n=6) treated dams. x-y Significance of means without common letters 


















Figure 3.35 Fetal Longissimus dorsi primary to secondary muscle fibers from fetuses 

















Figure 3.36 Fetal Longissimus dorsi PAX7 activated nuclei to total nuclei from fetuses 
harvested from CON (n=6) vs. MEL (n=6) treated dams. x-y Tendencies of 

















Figure 3.37 Fetal Longissimus dorsi total nuclei to total muscle fibers from fetuses 

















Figure 3.38 Fetal Longissimus dorsi average primary muscle fiber cross-sectional area 

















Figure 3.39 Fetal Longissimus dorsi average secondary muscle fiber cross-sectional 


















Figure 3.40 Fetal Longissimus dorsi immunohistochemistry in calves CON (n=6), MEL 
(n=6). Scale bar is 200 µm in length. Image A. immunofluorescent staining 
of dystrophin, C-terminal antibody (Red; PA1-37587, Thermo Scientific, 
Waltham, MA). Image B. immunofluorescent staining of BA-D5, myosin 
heavy chain IgG2b, (Yellow; Developmental Studies Hybridoma Bank, 
University of Iowa, Iowa City, IA). Image C. immunofluorescent staining 
of nuclei, Hoescht (Blue; CAT # 33342, Thermo Scientific, Waltham, 
MA). Image D. immunofluorescent staining of PAX7, hybridoma cell 
supernatant (Green; Developmental Studies Hybridoma Bank). Image E. 
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EFFECT OF MATERNAL MELATONIN SUPPLEMENTATION DURING LATE 
GESTATION ON NEONATAL LOIN MUSCLE GENE EXPRESSION DURING 
EARLY POSTNATAL LIFE 
4.1 Abstract 
Melatonin is a natural hormone that is secreted by the pineal gland and has effects 
on economically important reproductive and carcass tissues including muscle and adipose 
tissue. Supplemental melatonin during gestation increased postnatal weight of calves 
starting at 8 weeks of age (Brockus et al., 2016). The objectives of the study were to 
determine the effects of maternal melatonin supplementation during late gestation on 
relative gene expression in the Longissimus dorsi (LM) of bovine offspring. Beef heifers 
(n = 32) and cows (n = 25) consisting of purebred Angus, purebred Hereford, or 
crossbred genetics, were bred via timed-artificial insemination and assigned to one of two 
treatment groups. The treatment groups consisted of melatonin supplementation (MEL) 
or without supplementation (CON). Supplementation of MEL was delivered via two- 24 
mg implants with the CON receiving two placebo implants at days 180, 210, and 240 of 
gestation. After day 240 of gestation, dams received no further treatments. At the time of 
parturition (d 0), Longissimus dorsi biopsies of the calves were collected to undergo gene 
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expression via qPCR analysis. Maternal supplementation of MEL during late gestation 
resulted in no difference (P > 0.05) in calf birth weights between treatments, however, 
calves from MEL treated dams averaged 20 kg body weight increase (P = 0.03) at d 195 
compared to calves from CON dams. There were no differences (P > 0.05) between 
treatment groups for observed LM adipogenic and fibrogenic relative gene expressions. 
Though calves from MEL treated dams have a tendency for increased (P = 0.09) AMPK 
relative expression at birth, with increased MyoD (P = 0.04), IGF2 (P = 0.01), and a 
tendency for increased IGF1 (P = 0.05), by d 195 of age. At birth and d195, specific 
genes that are responsible for muscle metabolism and accretion have shown to be 
increased that can aid in superior muscle growth compared to calves from CON dams. 
Further testing of important time periods such as weaning, yearling, and harvesting could 
provide important data into the long-term changes as the animal continues to grow and 
develop until reaching market. 
4.2 Introduction 
With the rapidly increasing global population, the need for improving the 
efficiency of livestock in terms of meat production is vital. Prenatal myogenic and 
adipogenic development are a large determinant of the animal’s future postnatal 
production potential. Economically important tissues such as muscle and adipose are of a 
lower developmental priority compared to vital organs and nervous tissues (Zhu et al., 
2006; Du et al., 2010). This leaves muscle and adipose tissue development particularly 
susceptible to the prevailing nutritional environment in utero (Zhu et al., 2006; Du et al., 
2010). Stimuli and insults during the development of these tissues can set the stage for 
increased production efficiency, maximal growth, and superior carcasses, or lead to 
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impaired growth, inferior carcass composition, and increased risk of morbidity and 
mortality. Fetal programming is a change in the growth trajectory due to a stimulus or 
insult during a critical time in development for the fetus resulting in persisting effects into 
the postnatal phases of life or production (Nathanielsz et al., 2007). The first of these 
critical time points in growth for livestock is during prenatal development, at which point 
the fetus is completely dependent on the dam for nutrients. Nutrients for the fetus are in 
maternal circulation and must cross over to the fetus through the placenta. The nutritional 
status of the dam can have long lasting effects on fetal development by permanently 
altering the development of adipogenesis, fibrogenesis, and myogenesis (Karunaratne et 
al., 2005; Rehfeldt and Kuhn, 2006; Zhu et al., 2006; Funston et al., 2010; Huang et al., 
2010; Duarte et al., 2014; Wang et al., 2017).  
Approaches to prevent or rescue compromised pregnancies include identifying 
agents and mechanisms to improve uteroplacental nutrient exchange and in turn augment 
the in utero nutritional environment experienced by the fetus. Among these, 
supplementation of melatonin has been investigated as a novel therapeutic approach to 
increase uteroplacental blood flow (Lemley et al., 2012 and 2013; Brockus et al., 2016). 
Melatonin is a natural hormone produced from the pineal gland and derived from 
tryptophan. Melatonin has been described as having pleiotropic properties acting as a 
vasodilator, strong antioxidant, and signaling molecule for regulating natural circadian 
rhythm (Richter et al., 2009). The known melatonin receptors include MT1 and MT2 
(Dubocovich et al., 1998, 2010) and their presence has been detected on peripheral 
tissues including muscle (Stratos et al., 2012) and adipose tissue (Le Gouic et al., 1997). 
In skeletal muscle, binding of melatonin to these receptors stimulates glucose transport 
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into muscle cells (Ha et al., 2006), increases the number of satellite cells, reduces 
inflammation, and inhibits apoptosis by modulating associated signaling pathways 
(Stratos et al., 2012). Melatonin increased insulin receptor substrate-1 is phosphorylated 
and the activity of phosphatidylinositol 3-kinase is increased, resulting in increased 
glucose uptake (Ha et al., 2006). Studies have found melatonin to cause increased hair 
follicle growth in goats (Nixon et al.,1993), cardiovascular influence (Pechanova et 
al.,2014), and decreased core body temperature in humans (Krauchi et al.,1997). 
However, studies looking at similar effects in cattle was lacking. A study conducted by 
Brockus et al. (2016) supplemented Holstein heifers with melatonin to look at effects on 
offspring blood pressure, heart rate, liver blood flow, skin temperature, and hair growth. 
They found that calves from dams supplemented with melatonin during their last 
trimester of gestation, had significantly higher body weights at weeks 8 and 9 of age 
(Brockus et al., 2016). They hypothesized that melatonin supplementation could have 
altered skeletal muscle development of the calves, providing impetus for the current 
study (Brockus et al., 2016). 
This lead us to investigate the effects of MEL supplementation on skeletal muscle 
by collecting the entire fetal LM muscle to look at different morphometric measurements 
consisting of weight, circumference, and length, as outline in Section 3.3. Maternal 
supplementation of MEL during late gestation resulted in fetal LM tending to weigh more 
and be longer than that of calves from CON treated dams (Section 3.4). Also, analysis 
with immunohistochemistry showed calves from dams treated with MEL having a 
tendency for increased PAX7 activated nuclei to total nuclei ratio. This is important as 
the activation of PAX7 is required for fetal myoblast formation, and PAX7+ progenitor 
 
124 
cells act as a foundation and give rise to myogenic cells necessary for fetal skeletal 
muscle accretion (Hutcheson et al., 2009). Skeletal muscle being a heterogenous tissue, 
and MEL known effects on adipose metabolism (Elliott et al., 1989; Puchalski et al., 
2003; Raskind et al., 2007; Korhonen et al., 2008), lead us to collect plasma samples 
consisting of: fetal umbilical artery and vein plasma, fetal trunk plasma, and maternal 
plasma a long with fetal perirenal (PR) adipose tissue, as outlined in Section 3.3. To 
summarize the findings, calves from MEL supplemented dams had decreased adipogenic 
relative gene expression in PR adipose tissue (Table 3.17). To investigate the effects on 
calves from MEL treated dams, we decided to use a longitudinal approach looking at the 
postnatal development of their offspring at birth and d 195 of age. 
Therefore, our hypothesis was that increased maternal melatonin concentration 
during late gestation will lead to calves with altered metabolic programing of postnatal 
skeletal muscle. Additionally, the increased uterine blood flow will improve postnatal 
growth by programming increased myogenic mRNA gene expression in postnatal skeletal 
muscle. The specific objectives of the study were to determine the effects of maternal 
melatonin supplementation during late gestation on gene expression in the Longissimus 
dorsi (LM) of bovine offspring. 
4.3 Materials and Methods 
4.3.1 Animal Care and Treatment 
The current study was conducted under an approved Mississippi State University 
Institutional Animal Care and Use Committee protocol (#16-036). 
A total of 87 heifers and 65 cows that consisted of purebred Angus, purebred 
Hereford, or crossbred genetics, were bred via timed-artificial insemination (AI) at the H. 
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H. Leveck Animal Research Center. Heifers were bred on December 10, 2015, and cows 
were bred on December 21, 2015. At 120 days post-AI, heifers and cows were examined 
via ultrasonography to confirm pregnancy. This resulted in 32 heifers and 25 cows with 
confirmed conception. Then dams were blocked by bodyweight and randomly assigned to 
one of 2 maternal treatment groups. The 2 maternal treatment groups consist of a 
melatonin treatment (MEL; n = 29) and a no melatonin treatment (CON; n = 28). The 
MEL group was administered two ear impants (MelatoninImplants.com) containing 
24mg MEL each, every 30 days starting at d 180 of gestation (baseline) and ending on d 
240 of gestation. The MEL implant on d 240 of gestation was expected to provide 
increased maternal MEL concentration approximately till d 270 of gestation. After d 270 
of gestation, all dams received no further treatments throughout the study. Both maternal 
treatment groups were managed the same throughout the study and had access to similar 
dietary regimes with ad libitum water access. Within 24 hours of parturition (d 0), calves 
were weighed, tattooed, ear tagged, serum and plasma collected, and live muscle biopsies 
of the LM taken with subsequent samples collected at 195 d of age (d 195).  
4.3.2 Longissimus dorsi biopsy collection 
Muscle biopsy samples were collected from 35 calves on day 0 of age (CON = 17, 
MEL = 18) to serve as a biological baseline for the study. At day 195 of age, 31 calves 
(CON = 15, MEL = 16) had a second LM biopsy collected to analyze for changes in 
mRNA gene expression. Four of the calves were removed from this study because they 
required special management and their day 0 data will not be included. The landmark for 
the biopsies was located behind the 13th rib, in the middle of the muscle relative to the 
lumbar vertebra, on the left side of each calf. After cleaning the biopsy site, 1 cc of 
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Lidocaine (Aspen, Liberty, MO) was injected to provide local analgesia. After allowing 
sufficient time for the anesthetic, a 14-gauge piercing needle was used to penetrate fully 
through the skin. Then three biopsies of approximatly1g each of LM tissue were 
extracted using a 14-gauge x 9 cm Quick-Core® Biopsy Needle (COOK, Bloomington, 
IN) behind the 13th rib. The biopsy needle was inserted through the punctured skin at a 
45-degree angle relative to the LM fibers. Tissue samples were stored in cryotubes at -
80°C until further analysis. 
4.3.3 Longissimus dorsi Analysis of Relative Gene Expression 
4.3.3.1 QuantiNova™ SYBR® Green PCR Kit 
Nucleic acids were isolated from the LM biopsy samples using 700 μl of QIAzol® 
Lysis Reagent (QIAGEN, Hilden, Germany), followed by purification with the use of 
RNA using a miRNeasy® Mini Kit (QIAGEN, Hilden, Germany). Extracted total RNA 
was quantified using a NanoDrop One spectrophotometer (Thermo scientific, Waltham, 
MA). Samples exhibiting 260 nm/280 nm ratios between 1.9 and 2.1 were deemed 
acceptable for downstream procedures and stored at -80°C. For each sample, duplicate 
cDNA synthesis reactions were conducted using 100 ng of total RNA using 
QuantiNova™ Reverse Transcription Kits (QIAGEN, Hilden, Germany) according to the 
manufacturers protocol. The genes of interest for LM tissue cystatin (CYS), adenosine 
monophosphate-activated protein kinase-α (AMPK). Beta actin was used as a 
housekeeping gene. Gene specific primers for the genes of interest (Table 4.1) were 
designed and validated for quantitative PCR (qPCR). Primer efficiencies were 
determined by plotting the threshold cycle versus the log of the input concentrations for 
8, 10-fold serial dilutions of pooled LM muscle cDNA. Primer sets and assays with 
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efficiencies between 0.9 and 1.1 were considered acceptable for real time PCR analysis. 
Each of the duplicate cDNA samples were subjected to duplicate qPCR reactions using 
QuantiNova™ SYBR® Green PCR Kit (QIAGEN, Hilden, Germany). A master mix 
containing SYBR® Green, forward and reverse primers (diluted 1:20), and ROX reference 
dye along with 112.5 ng of cDNA was pipetted into a 96-well MicroAmp® Fast Optical 
Reaction Plate (Applied Biosystems, Foster City, CA). The plate was then covered with 
Masterclear real-time PCR Film (Eppendorf, Hamburg, Germany), briefly vortexed and 
centrifuged, then placed in QuantiStudio™ 3 (Applied Biosystems, Foster City, CA) for 
real-time qPCR analysis. Thermal cycling parameters used consisted of: a hold stage at 
95°C for 2 minutes; PCR stage with step 1 at 95°C for 5 seconds followed by step 2 at 
60°C for 10 seconds for 50 cycles; with a melting curve stage have step 1 at 95°C for 1 
second then step 2 60°C for 20 seconds and step 3 (dissociation) at 95°C for 1 second 
(capturing every 0.1°C/s). Replicate threshold cycle (CT) values were averaged and used 
for relative quantification using the 2−ΔΔCT method (Livak and Schmittgen, 2001). 
4.3.3.2 TaqMan™ fast advanced master mix 
Nucleic acids were isolated from the LM biopsy samples using 700 μl of 
QIAzol® Lysis Reagent (QIAGEN, Hilden, Germany), followed by purification with the 
use of RNA using a miRNeasy® Mini Kit (QIAGEN, Hilden, Germany). Extracted total 
RNA was quantified using a NanoDrop One spectrophotometer (Thermo scientific, 
Waltham, MA). Samples exhibiting 260 nm/280 nm ratios between 1.9 and 2.1 were 
deemed acceptable for downstream procedures and stored at -80°C. For each sample, 
duplicate cDNA synthesis reactions were conducted using 100 ng of total RNA using 
QuantiNova™ Reverse Transcription Kits (QIAGEN, Hilden, Germany) according to the 
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manufacturer protocol. The genes of interest for LM were insulin-like growth factor 1 
(IGF1), IGF1 receptor (IGF1R), insulin-like growth factor 2 (IGF2), IGF2 receptor 
(IGF2R), myogenic factor 5 (Myf5), myogenin (MyoG), myogenic differentiation 1 
(MyoD), stearoyl-CoA desaturase (SCD), peroxisome proliferator activated receptor 
gamma (PPARg), and patatin-like phospholipase domain containing 2 (PNPLA2). Beta 
actin was used as a housekeeping gene. Assays for the genes of interest (Table 4.2) were 
validated for efficiency and specificity prior to qPCR. Primer efficiencies were 
determined by plotting the threshold cycle versus the log of the input concentrations for 
8, 10-fold serial dilutions of pooled PR adipose tissue cDNA. Primer sets and assays with 
efficiencies between 0.9 and 1.1 were considered acceptable for real time PCR analysis. 
Complementary DNA was amplified in duplicate using TaqMan™ fast advanced master 
mix (Thermo scientific, Waltham, MA). A master mix containing TaqMan™ fast 
advanced master mix and gene assay was pipetted along with 37.5 ng of cDNA into a 96-
well MicroAmp® Fast Optical Reaction Plate (Applied Biosystems, Foster City, CA). 
The plate was then covered with Masterclear real-time PCR Film (Eppendorf, Hamburg, 
Germany), briefly vortexed and centrifuged, then placed in QuantiStudio™ 3 (Applied 
Biosystems, Foster City, CA) for real-time qPCR analysis. Thermal cycling parameters 
used consisted of: a hold stage at 50°C for 2 minutes; polymerase activation hold at 95°C 
for 20 seconds; PCR stage with step 1 at 95°C for 1 second followed by step 2 at 60°C 
for 20 seconds for 40 cycles. Replicate CT values were averaged and used for relative 
quantification using the 2−ΔΔCT method (Livak and Schmittgen, 2001). 
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4.3.4 Statistical Analysis 
Gene expressions and morphometrics were analyzed using MIXED procedure of 
the Statistical Analysis System (SAS software version 9.4, SAS Institute, Cary, NC, 
USA). Where the model statement included: treatment, calf sex, treatment x calf sex 
interaction, parity, treatment x parity interaction, and breed of dam, treatment x breed, 
calf day of age, and treatment x day interaction. Data found to be nonnormally distributed 
were tested using the Wilcoxon rank sum test. Gestation length served as covariate for d 
0 with d 195 having age of calf as covariate. Least square means and standard error of the 
means were reported. Pairwise comparisons between the least squares means of the factor 
levels were computed using the PDIFF option of the LSMEANS statement. Statistical 
significance was determined at P ≤ 0.05, and P-values falling within P > 0.05 and P ≤ 
0.10 were considered a trend. 
4.4 Results 
4.4.1 D 0 Morphometric Analysis 
Birth weight was not different (P > 0.05) in calves from MEL treated dams 
compared to calves from CON treated dams (Table 4.3; Figure 4.1). 
4.4.2 D 0 Longissimus dorsi Relative Gene Expression Analysis 
At d 0, LM relative gene expression did not differ (P > 0.05) for the following: 
CYS, IGF1, IGF1R, IGF2, IGF2R, MyoG, MyoD, Myf5, PPARg, PNPLA2, or SCD 
between calves from MEL compared to CON dams (Table 4.4, 4.5; Figures 4.3, 4.5-
4.14). At d 0, LM relative gene expression of AMPK tended to be increased (P = 0.09) in 
calves from MEL compared to CON dams (Table 4.4; Figure 4.4). 
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4.4.3 Day 195 Morphometric Analysis 
At d 195, calf body weight was increased (P = 0.03) in calves from MEL treated 
dams compared to calves from CON treated dams (Table 4.3 Figure 4.2). 
4.4.4 Day 195 Longissimus dorsi Relative Gene Expression Analysis 
At d 195, LM relative gene expression did not differ (P > 0.05) for the following: 
CYS, AMPK, IGF1R, IGF2R, MyoG, Myf5, PPARg, PNPLA2, or SCD between calves 
from MEL compared to CON dams (Table 4.4, 4.5; Figures 4.3, 4.4, 4.6, 4.8, 4.9, 4.11-
4.14). However, LM relative gene expression was increased for IGF2 (P = 0.01) and 
MyoD (P = 0.04) with IGF1 tending to be increased (P = 0.05) between calves born from 
MEL treated dams compared to CON dams (Tables 4.5; Figures 4.5, 4.7, 4.10). 
4.5 Discussion 
 Brockus and colleagues, found that Holstein calves from MEL treated dams had 
no difference in birth weight but had an increased body weight starting at 8 weeks of age 
compared to calves from CON dams (2016). The authors believed that MEL 
supplementation to Holstein dams during late gestation may have caused a programmed 
response leading to a change in fetal skeletal muscle development that potentially caused 
the increased weight gain (Brockus et al., 2016). To investigate this hypothesis, we 
conducted twelve fetal necropsies collecting LM muscle, perirenal (PR) adipose, 
umbilical artery and vein plasma, fetal trunk plasma, and maternal plasma samples, as 
outlined in Section 3.3. The reason for examining fetal muscle and adipose tissue was to 
observe if MEL supplementation to dams during late gestation had any effects on 
myogenesis and adipogenesis. The full report of the results from the fetal portion of this 
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study are shown in Section 3.4. To summarize, maternal supplementation of MEL during 
late gestation does impact fetal calf LM muscle and PR adipose tissue development by d 
240 of gestation. The next step to investigate the claim of increased postnatal calf body 
weight lead us to conducting a postnatal trial.  
In this postnatal study, there was no difference in calf birth weights between 
treatment groups, which is consistent with the findings of Brockus et al. (2016). 
However, calves born from MEL treated dams at d 195 weighed an average of 20 kg 
more than calves from CON dams. This supports the findings of Brockus and colleagues 
as they observed Holstein calves from MEL treated dams to have increased body weights 
starting at 8 weeks of age compared to calves from CON dams (2016). Live biopsies of 
LM muscle tissue were collected at d 0 and d 195 of age to look at postnatal relative gene 
expression of myogenic, adipogenic, and fibrogenic genes as well as genes responsible 
for muscle and adipose metabolism (Tables 4.1, 4.2).  
Upon qPCR analysis of cDNA from d 0 LM muscle tissue, supplementation of 
MEL during late gestation caused no change in myogenic or adipogenic relative gene 
expression compared to that of CON, which is consistent with the fetal results in Section 
3.4. However, at the time of birth, LM tissue of calves from MEL treated dams had no 
difference (P > 0.05) in CYS relative gene expression compared to calves from CON 
dams. This is surprising as MEL supplementation lead to fetal calves at 240 days of 
gestation with increased (P = 0.02) CYS relative gene expression compared to calves 
from CON dams (Table 3.15). The reason behind the change in expression between 240 
days of gestation to birth and the implications are unclear. After analysis of metabolic 
related genes in LM tissue, we found that IGF1, IGF1R, IGF2, and IGF2R were not 
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different between treatment groups apart from AMPK, which tended to be increased (P = 
0.09). This is identical to fetal results outlined in Section 3.4 except for AMPK which 
was significantly increased (P = 0.03) in fetal calves from MEL treated dams. Based on 
these results at the time of birth, calves from MEL supplemented dams had similar 
myogenic, adipogenic, and fibrogenic relative gene expression to that of calves from 
CON dams. However, the enhanced LM tissue energy metabolism provided by the 
elevated AMPK levels could support superior muscle accretion.  
To further investigate the observed increase in d 195 body weight, we conducted 
qPCR analysis of cDNA from d 195 LM muscle tissue. There were no changes in calf 
LM myogenic, adipogenic, and fibrogenic relative gene expressions; except for MyoD, 
which was increased in calves born from MEL treated dams. The postnatal expression of 
MyoD in skeletal muscle is involved with satellite cells differentiation (Grand and 
Rudnicki, 2007). In the normal, uninjured postnatal animal, MyoD and other myogenic 
regulatory factor gene expressions are either very low or undetectable in quiescent 
satellite cells (Beilhartz et al., 1992; Buonanno et al., 1992; Eftimie et al., 1991). 
However, muscle stress caused by weight bearing or trauma results in the activation of 
satellite cells from a quiescent state to a proliferative state (Grand and Rudnicki, 2007). 
The activated satellite cells then begin to express increased levels of MyoD, which 
ultimately causes them to differentiate into myoblasts and then fuse with myofibers to 
help with myofiber regeneration (Koishi et al., 1995; Yablonka-Reuveni, 1995; Dhawan 
and Rando, 2005; Grand and Rudnicki, 2007). The increased LM relative gene 
expression of MyoD in d 195 calves born from MEL treated dams could aid in muscle 
hypertrophy and regeneration supporting enhanced muscle accretion compared to calves 
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from CON dams. Lastly, there were no changes in IGF1R, IGF2R, or AMPK in d 195 
calf LM between treatment groups. Although, IGF2 was increased (P = 0.01) in d 195 
calves born from MEL treated dams and they had a tendency for increased IGF1 (P = 
0.05) compared to calves from CON dams. In skeletal muscle growth and development, 
IGF2 is the predominant IGF in fetal development with IGF1 being the primary growth 
factor responsible for increased postnatal protein synthesis and muscle hypertrophy 
(Florini et al., 1991; Haig and Graham, 1991; Braxton et al., 1993; Bass et al., 1999; Le 
Roith et al., 2001; Gluckman and Pinal, 2003; Gonzalez et al., 2013; Wang and Mitch, 
2014). In fetal skeletal muscle, IGF2 assists in myoblast cell growth and differentiation 
and via the mTOR pathway (Erbay et al., 2003; Glass, 2010; Dai et al., 2011; 
Hornberger, 2011; Ge and Chen, 2012). Current literature on the importance of IGF2 in 
postnatal animal is currently lacking as levels of IGF2 in postnatal animals is very low 
(Clark et al., 2015). However, some literature observing the effects of mutations that 
caused elevated levels of postnatal IGF2 have shown to increase skeletal muscle mass of 
pigs (Gardan et al., 2008a; Gardan et al., 2008b). The effects of IGF1 on postnatal muscle 
accretion has been shown to be a combination of satellite cell activation and increasing 
protein synthesis in myofibers (Barton-Davis et al., 1999; Machida and Booth, 2004).  
In Summary, maternal supplementation of MEL during late gestation does impact 
LM muscle relative gene expression of calves at birth and d 195 of age. At birth and 
d195, specific genes that are responsible for muscle metabolism and accretion have 
shown to be increased. With increased muscle energy metabolism and protein synthesis, 
these calves could support superior muscle growth compared to calves from CON dams. 
One limitation to this study is the absence of postnatal LM samples for 
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immunohistochemical (IHC) analysis and perirenal adipose for qPCR and IHC analysis. 
Future research will be needed to provide additional information on the effects of MEL 
supplementation to dams during late gestation on their offspring’s performance from 




















Table 4.1  Accession, sequences, amplicon length, and efficiency of primers used for 
QuantiNovaTM SYBR® Green real-time PCR quantification of Longissimus 
dorsi gene expression. 








































NM_173979  GTCGACACCGCAACCAGTT  AAGCCGGCCTTGCACAT  85 0.94 
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Table 4.2 Assays, accession, amplicon length, and efficiency of primers used for 
TaqMan® real-time PCR quantification of Longissimus dorsi gene 
expression. 
Gene1 Assay ID Accession  Amplicon Size Efficiency 
Beta Actin Bt03279174_g1  NP_776404 141 0.96 
Myf5 Bt03223134_m1  NP_776541 98 0.95 
MyoG Bt03258928_m1 NP_001104795.1 96 0.96 
MyoD Bt03244740_m1 NP_001035568.2 84 0.95 
SCD Bt04307478_m1 NP_776384.3 89 0.97 
PPARg Bt03217547_m1  NP_851367.1 85 0.93 
PNPLA2 Bt03234128_m1 NP_001039470.1 77 0.98 
IGF1 Bt03252282_m1 NM_001077828.1 65 0.99 
IGF1R Bt03649217_m1  NP_001231541.1 70 0.93 
IGF2 Bt03259225_m1 NP_776512.2 54 0.95 
IGF2R Bt03223452_m1 NP_776777.1 57 0.97 
1 Myf5 = myogenic factor 5, MyoG = myogenin, MyoD = myogenic differentiation 1, 
SCD = stearoyl-CoA desaturase, PPARg = peroxisome proliferator activated receptor 
gamma, PNPLA2 = patatin-like phospholipase domain containing 2, IGF1 = insulin-like 














Table 4.3 Morphometric body weight measurements of newborn (d0) calves and at 
195 days of age (d195) from heifers and cows treated with CON (n=17) 
and MEL (n=18). 
 Morphometric Measurements 
 Treatment 
Measurements CON MEL SEM P Value 
d0 BW (kg) 29.2962 30.0535 2.1489 0.73 
d195 BW (kg) 203.6800a 222.9200b 8.4327 0.03 



















Table 4.4 QuantiNovaTM SYBR® Green real-time PCR quantification of day 0 and 
day 195 of age calf Longissimus dorsi (LM) PCR relative expression of 
IGF1, IGF1R, IGF2, IGF2R, BMP, CYS, LOX, and AMPK of calves CON 
(n=15) and MEL (n=12). 
  Longissimus dorsi PCR Relative Expression 
  Treatment 
Gene1 Day CON MEL SEM P Value 
CYS 0 13.6312 14.0463 1.8188 0.82 
AMPK 0 11.6610x 16.0537y 2.3984 0.09 
CYS 195 12.9846 15.7637 2.1501 0.22 
AMPK 195 9.7948 13.4842 2.1658 0.11 
x–y Means within a row without common superscript represent tendencies (P ≥ 0.05 and P 
≤ 0.10)  

















Table 4.5 TaqMan® real-time PCR quantification of Fetal Longissimus dorsi (LM) 
PCR relative expression of IGF1, IGF1R, IGF2, IGF2R, BMP, CYS, LOX, 
and AMPK of calves CON (n=15) and MEL (n=12). 
 Longissimus dorsi PCR Relative Expression 
 Treatment 
Gene Day CON MEL SEM P Value 
IGF1 0 16.3649 12.6753 2.4820 0.16 
IGF1R 0 15.1188 13.8071 2.8333 0.65 
IGF2 0 15.3318 11.2373 3.1644 0.21 
IGF2R 0 12.2895 15.1951 3.3600 0.40 
MyoG 0 10.5495 14.4845 3.3174 0.25 
MyoD 0 13.2074 15.2774 3.0557 0.51 
Myf5 0 13.4810 13.5475 2.6275 0.98 
PPARG 0 14.6599 12.4148 2.8657 0.44 
PNPLA2 0 13.5073 15.5713 2.4724 0.42 
SCD 0 13.6577 9.9399 3.1103 0.25 
IGF1 195 11.3291x 16.3203y 2.3612 0.05 
IGF1R 195 13.8416 15.2951 2.7761 0.61 
IGF2 195 10.8386a 19.1387b 2.6646 0.01 
IGF2R 195 15.2453 16.0937 2.7091 0.76 
MyoG 195 14.7130 18.1307 2.5274 0.20 
MyoD 195 12.5768a 18.7497b 2.8189 0.04 
Myf5 195 13.0385 14.1356 2.9276 0.71 
PPARG 195 14.4667 15.5676 3.0531 0.72 
PNPLA2 195 13.8538 13.5899 2.6193 0.92 
SCD 195 13.7654 15.6272 2.5418 0.47 
a–b Means within a row without common superscript differ (P < 0.05) 
x–y Means within a row without common superscript represent tendencies (P ≥ 0.05 and P 
≤ 0.10) 
1 Myf5 = myogenic factor 5, MyoG = myogenin, MyoD = myogenic differentiation 1, 
CEBPA = CCAAT enhancer binding protein alpha, SCD = stearoyl-CoA desaturase, 
PPARg = peroxisome proliferator activated receptor gamma, PNPLA2 = patatin-like 
phospholipase domain containing 2, IGF1 = insulin-like growth factor 1, IGF1R = IGF1 








Figure 4.1 Birth weight (d 0) average from offspring born from CON (n=15) or MEL 









Figure 4.2 Body weight (d 195) average from offspring born from CON (n=15) or 
MEL (n=12) treated dams. a–b Means within a row without common 














Figure 4.3 Relative expression (mRNA abundance) of cystatin in Longissimus dorsi 













Figure 4.4 Relative expression (mRNA abundance) of adenosine monophosphate-
activated protein kinase-α in Longissimus dorsi from day 0 and day 195 
offspring born from CON (n=15) or MEL (n=12) treated dams. x–y Means 
within a row without common superscript represent tendencies (P ≥ 0.05 


















Figure 4.5 Relative expression (mRNA abundance) of Insulin-Like Growth factor 1 in 
Longissimus dorsi from day 0 and day 195 offspring born from CON 
(n=15) or MEL (n=12) treated dams. x–y Means within a row without 















Figure 4.6 Relative expression (mRNA abundance) of Insulin-Like Growth factor 1 
receptor in Longissimus dorsi from day 0 and day 195 offspring born from 














Figure 4.7 Relative expression (mRNA abundance) of Insulin-Like Growth factor 2 in 
Longissimus dorsi from day 0 and day 195 offspring born from CON 
(n=15) or MEL (n=12) treated dams. a–b Means within a row without 















Figure 4.8 Relative expression (mRNA abundance) of Insulin-Like Growth factor 2 
receptor in Longissimus dorsi from day 0 and day 195 offspring born from 














Figure 4.9 Relative expression (mRNA abundance) of myogenin in Longissimus dorsi 















Figure 4.10 Relative expression (mRNA abundance) of myogenic differentiation 1 in 
Longissimus dorsi from day 0 and day 195 offspring born from CON 
(n=15) or MEL (n=12) treated dams. a–b Means within a row without 















Figure 4.11 Relative expression (mRNA abundance) of myogenic factor 5 in 
Longissimus dorsi from day 0 and day 195 offspring born from CON 














Figure 4.12 Relative expression (mRNA abundance) of peroxisome proliferator 
activated receptor gamma in Longissimus dorsi from day 0 and day 195 














Figure 4.13 Relative expression (mRNA abundance) of patatin-like phospholipase 
domain containing 2 in Longissimus dorsi from day 0 and day 195 














Figure 4.14 Relative expression (mRNA abundance) of stearoyl-CoA desaturase in 
Longissimus dorsi from day 0 and day 195 offspring born from CON 
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